CN105085530B - Ternary condenses cyclosubstituted amino hexatomic ring analog derivative and its application in medicine - Google Patents
Ternary condenses cyclosubstituted amino hexatomic ring analog derivative and its application in medicine Download PDFInfo
- Publication number
- CN105085530B CN105085530B CN201510267948.8A CN201510267948A CN105085530B CN 105085530 B CN105085530 B CN 105085530B CN 201510267948 A CN201510267948 A CN 201510267948A CN 105085530 B CN105085530 B CN 105085530B
- Authority
- CN
- China
- Prior art keywords
- salt
- alkyl
- tetrahydro
- base
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract description 38
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 239000003112 inhibitor Substances 0.000 claims abstract description 20
- 229940002612 prodrug Drugs 0.000 claims abstract description 16
- 239000000651 prodrug Substances 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- -1 amine salt Chemical class 0.000 claims description 205
- 239000000203 mixture Substances 0.000 claims description 31
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 16
- 239000011734 sodium Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229940077388 benzenesulfonate Drugs 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 8
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 8
- 229940123208 Biguanide Drugs 0.000 claims description 7
- 150000004283 biguanides Chemical class 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 6
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 6
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 6
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 239000000837 restrainer Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 229940100389 Sulfonylurea Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 229960004937 saxagliptin Drugs 0.000 claims description 5
- 108010033693 saxagliptin Proteins 0.000 claims description 5
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 5
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 5
- 229960004034 sitagliptin Drugs 0.000 claims description 5
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 5
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 claims description 4
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical group C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 4
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 claims description 4
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 4
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 4
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical group C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 4
- 229950009226 ciglitazone Drugs 0.000 claims description 4
- 229960003834 dapagliflozin Drugs 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 4
- 229950003693 dutogliptin Drugs 0.000 claims description 4
- 150000002169 ethanolamines Chemical class 0.000 claims description 4
- 229960004580 glibenclamide Drugs 0.000 claims description 4
- 229960001764 glibornuride Drugs 0.000 claims description 4
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 claims description 4
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 4
- 229960004346 glimepiride Drugs 0.000 claims description 4
- 229960003468 gliquidone Drugs 0.000 claims description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 229960002397 linagliptin Drugs 0.000 claims description 4
- 229960001110 miglitol Drugs 0.000 claims description 4
- 229960003365 mitiglinide Drugs 0.000 claims description 4
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 claims description 4
- 229960000698 nateglinide Drugs 0.000 claims description 4
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical group C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229960005095 pioglitazone Drugs 0.000 claims description 4
- 229960002354 repaglinide Drugs 0.000 claims description 4
- 229960004586 rosiglitazone Drugs 0.000 claims description 4
- 229940126842 sergliflozin Drugs 0.000 claims description 4
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 claims description 4
- 159000000000 sodium salts Chemical group 0.000 claims description 4
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 4
- 229960001641 troglitazone Drugs 0.000 claims description 4
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 4
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 4
- 229960001254 vildagliptin Drugs 0.000 claims description 4
- 229960001729 voglibose Drugs 0.000 claims description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 3
- JSYGLDMGERSRPC-FQUUOJAGSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-FQUUOJAGSA-N 0.000 claims description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 3
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims description 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 3
- 108010011459 Exenatide Proteins 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
- 229960002632 acarbose Drugs 0.000 claims description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 229940114081 cinnamate Drugs 0.000 claims description 3
- 150000003946 cyclohexylamines Chemical class 0.000 claims description 3
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 229960001519 exenatide Drugs 0.000 claims description 3
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 229940049920 malate Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 3
- 229950009585 melogliptin Drugs 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- 229950004288 tosilate Drugs 0.000 claims description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 3
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 101710173663 Glucagon-1 Proteins 0.000 claims description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 159000000009 barium salts Chemical class 0.000 claims description 2
- 229940050390 benzoate Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229950007655 esilate Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229960000346 gliclazide Drugs 0.000 claims description 2
- 229940049906 glutamate Drugs 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 208000009928 nephrosis Diseases 0.000 claims description 2
- 231100001027 nephrosis Toxicity 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 150000003891 oxalate salts Chemical class 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 abstract description 39
- 239000002585 base Substances 0.000 description 199
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 147
- 150000001875 compounds Chemical class 0.000 description 117
- 239000000243 solution Substances 0.000 description 115
- 238000006243 chemical reaction Methods 0.000 description 98
- 125000000217 alkyl group Chemical group 0.000 description 82
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 62
- 229910052731 fluorine Inorganic materials 0.000 description 58
- 125000000623 heterocyclic group Chemical group 0.000 description 58
- 239000000460 chlorine Substances 0.000 description 54
- 229910052801 chlorine Inorganic materials 0.000 description 52
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 49
- 229910052794 bromium Inorganic materials 0.000 description 48
- 238000001819 mass spectrum Methods 0.000 description 48
- 239000012074 organic phase Substances 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 40
- 239000007787 solid Substances 0.000 description 40
- 150000003217 pyrazoles Chemical class 0.000 description 39
- 125000003545 alkoxy group Chemical group 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 36
- 229910052739 hydrogen Inorganic materials 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 125000001072 heteroaryl group Chemical group 0.000 description 34
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 32
- 235000002639 sodium chloride Nutrition 0.000 description 32
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000003756 stirring Methods 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 21
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- 125000004093 cyano group Chemical group *C#N 0.000 description 19
- 229910052740 iodine Inorganic materials 0.000 description 19
- 125000000753 cycloalkyl group Chemical group 0.000 description 17
- 239000001257 hydrogen Substances 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- 230000006837 decompression Effects 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 12
- 150000002367 halogens Chemical class 0.000 description 12
- 229950002366 nafoxidine Drugs 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 11
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 150000001299 aldehydes Chemical class 0.000 description 10
- 150000007942 carboxylates Chemical class 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- WUUOEJJGRCQGBQ-UHFFFAOYSA-N oxan-3-amine Chemical compound NC1CCCOC1 WUUOEJJGRCQGBQ-UHFFFAOYSA-N 0.000 description 10
- 238000006884 silylation reaction Methods 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000004185 ester group Chemical group 0.000 description 9
- 150000002431 hydrogen Chemical group 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000012266 salt solution Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 9
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- 239000005864 Sulphur Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 229960003328 benzoyl peroxide Drugs 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 7
- 229940092714 benzenesulfonic acid Drugs 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- JDAMVJVCYBSBJX-UHFFFAOYSA-N C1=CN=CN=C1.OS(=O)(=O)C1=CC=CC=C1 Chemical compound C1=CN=CN=C1.OS(=O)(=O)C1=CC=CC=C1 JDAMVJVCYBSBJX-UHFFFAOYSA-N 0.000 description 6
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 239000000908 ammonium hydroxide Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000013517 stratification Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 4
- 150000001447 alkali salts Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 229940127003 anti-diabetic drug Drugs 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- XOVJAYNMQDTIJD-UHFFFAOYSA-N cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- GUYMHFIHHOEFOA-ZCPGHIKRSA-N Carmegliptin Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@@H](CF)CC1=O GUYMHFIHHOEFOA-ZCPGHIKRSA-N 0.000 description 3
- 241000790917 Dioxys <bee> Species 0.000 description 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 3
- 108010019598 Liraglutide Proteins 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229960001713 canagliflozin Drugs 0.000 description 3
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229950003594 carmegliptin Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229960001381 glipizide Drugs 0.000 description 3
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 229960002701 liraglutide Drugs 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- ZEALVTCQQUVGAI-IJCUWJILSA-N tert-butyl N-[(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(4-methylsulfonyl-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2,5-dien-10-yl)oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=NN(C=C5C4C3)S(=O)(=O)C ZEALVTCQQUVGAI-IJCUWJILSA-N 0.000 description 3
- NLSWCGJEHKBBDT-NRHJLLRUSA-N (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[3-(trifluoromethyl)-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl]oxan-3-amine Chemical compound C1[C@H](CO[C@@H]([C@H]1N)C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C(=NN5)C(F)(F)F NLSWCGJEHKBBDT-NRHJLLRUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical compound CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- MREIFUWKYMNYTK-UHFFFAOYSA-N 1H-pyrrole Chemical class C=1C=CNC=1.C=1C=CNC=1 MREIFUWKYMNYTK-UHFFFAOYSA-N 0.000 description 2
- FFVYBYTXDLRBQQ-ABSCNWHNSA-N 2-[10-[(3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)oxan-3-yl]-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-5-yl]ethanol Chemical compound C1[C@H](CO[C@@H]([C@H]1N)C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C=NN5CCO FFVYBYTXDLRBQQ-ABSCNWHNSA-N 0.000 description 2
- AORCJACITFIFAU-PDRSGWLNSA-N 2-[10-[(3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)oxan-3-yl]-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2,5-dien-4-yl]ethanol Chemical compound C1[C@H](CO[C@@H]([C@H]1N)C2=C(C=CC(=C2)F)F)N3CC4CC5=NN(C=C5C4C3)CCO AORCJACITFIFAU-PDRSGWLNSA-N 0.000 description 2
- XCRCSPKQEDMVBO-UHFFFAOYSA-N 2-bromo-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(Br)=C1 XCRCSPKQEDMVBO-UHFFFAOYSA-N 0.000 description 2
- WWUVJRULCWHUSA-UHFFFAOYSA-N 2MP Natural products CCCC(C)=C WWUVJRULCWHUSA-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- DZAHXNNEQCZPGJ-UHFFFAOYSA-N CCCCOC(OC)=O.COC(O)=O Chemical class CCCCOC(OC)=O.COC(O)=O DZAHXNNEQCZPGJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108010086019 Secretin Proteins 0.000 description 2
- 102100037505 Secretin Human genes 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- QXAITBQSYVNQDR-ZIOPAAQOSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1/N=C/N(C)\C=N\C1=CC=C(C)C=C1C QXAITBQSYVNQDR-ZIOPAAQOSA-N 0.000 description 2
- 229960002587 amitraz Drugs 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 150000001924 cycloalkanes Chemical class 0.000 description 2
- LMKPHJYTFHAGHK-UHFFFAOYSA-N cyclodrine Chemical compound C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LMKPHJYTFHAGHK-UHFFFAOYSA-N 0.000 description 2
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 2
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical class CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 2
- 229950006689 darglitazone Drugs 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- QUGJYNGNUBHTNS-UHFFFAOYSA-N ethyl 2-(benzhydrylideneamino)acetate Chemical compound C=1C=CC=CC=1C(=NCC(=O)OCC)C1=CC=CC=C1 QUGJYNGNUBHTNS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- VWSAXEUPFOKXKN-BLFBOMFDSA-N methyl 10-[(3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)oxan-3-yl]-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-diene-3-carboxylate Chemical compound COC(=O)C1=NNC2=C1C3CN(CC3C2)[C@@H]4C[C@@H]([C@H](OC4)C5=C(C=CC(=C5)F)F)N VWSAXEUPFOKXKN-BLFBOMFDSA-N 0.000 description 2
- 239000010813 municipal solid waste Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960002101 secretin Drugs 0.000 description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OAJVVOWRMAHMCM-UHFFFAOYSA-N tert-butyl 3-(trifluoromethyl)-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-diene-10-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC3=C(C2C1)C(=NN3)C(F)(F)F OAJVVOWRMAHMCM-UHFFFAOYSA-N 0.000 description 2
- GXEQTSLDDGXNBY-KDQNWNSOSA-N tert-butyl N-[(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(5-methylsulfonyl-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl)oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C=NN5S(=O)(=O)C GXEQTSLDDGXNBY-KDQNWNSOSA-N 0.000 description 2
- OTCULXVRRSCLLI-UONOGXRCSA-N tert-butyl n-[(2r,3s)-2-(2,5-difluorophenyl)-5-oxooxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CC(=O)CO[C@@H]1C1=CC(F)=CC=C1F OTCULXVRRSCLLI-UONOGXRCSA-N 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- SQKAVTIFKGEHEW-HEYWDXOUSA-N (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(5-methylsulfonyl-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl)oxan-3-amine Chemical compound CS(=O)(=O)N1C2=C(C=N1)C3CN(CC3C2)[C@@H]4C[C@@H]([C@H](OC4)C5=C(C=CC(=C5)F)F)N SQKAVTIFKGEHEW-HEYWDXOUSA-N 0.000 description 1
- IWAURVJYDKDOEC-CBNSAJPESA-N (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[10-(trifluoromethyl)-4,9,11-triazatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-4-yl]oxan-3-amine Chemical compound C1[C@H](CO[C@@H]([C@H]1N)C2=C(C=CC(=C2)F)F)N3CC4CC5=NC(=NC=C5C4C3)C(F)(F)F IWAURVJYDKDOEC-CBNSAJPESA-N 0.000 description 1
- OBSLWIKITOYASJ-AZEWMMITSA-N (2r,3s,4s,5r,6s)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@@H]1[C@H](O)O[C@@H](CO)[C@H](O)[C@H]1O OBSLWIKITOYASJ-AZEWMMITSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- SOVOPSCRHKEUNJ-VQHVLOKHSA-N (e)-dec-4-ene Chemical compound CCCCC\C=C\CCC SOVOPSCRHKEUNJ-VQHVLOKHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical class C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 1
- KODLUXHSIZOKTG-UHFFFAOYSA-N 1-aminobutan-2-ol Chemical class CCC(O)CN KODLUXHSIZOKTG-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- JYZQJYHHWAITJQ-UHFFFAOYSA-N 1-methyl-4-propan-2-ylbenzene;ruthenium(2+) Chemical compound [Ru+2].CC(C)C1=CC=C(C)C=C1 JYZQJYHHWAITJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- YHTRFXWMECYSIT-UHFFFAOYSA-N 10-O-tert-butyl 3-O-methyl 4-(2-trimethylsilylethoxymethyl)-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2,5-diene-3,10-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC3=NN(C(=C3C2C1)C(=O)OC)COCC[Si](C)(C)C YHTRFXWMECYSIT-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- ZWVYQZBCSXCUOO-UHFFFAOYSA-N 2,3,4,5,6-pentafluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ZWVYQZBCSXCUOO-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- NJGWQPXRAZROQC-UHFFFAOYSA-N 2-(4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-5-yl)ethyl benzenesulfonate Chemical compound C1(=CC=CC=C1)S(=O)(=O)OCCN1N=CC2=C1CC1C2CNC1 NJGWQPXRAZROQC-UHFFFAOYSA-N 0.000 description 1
- DQWGGDXOGNQHBH-UHFFFAOYSA-N 2-(4,5,10-triazatricyclo[6.3.0.02,6]undeca-2,5-dien-4-yl)ethyl benzenesulfonate Chemical compound C1C2CNCC2C3=CN(N=C31)CCOS(=O)(=O)C4=CC=CC=C4 DQWGGDXOGNQHBH-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- AMKHAJIFPHJYMH-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-4-ynoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC#C AMKHAJIFPHJYMH-UHFFFAOYSA-N 0.000 description 1
- MCSJGXLZPITMIH-UHFFFAOYSA-N 2-aminobutane-1,1,1-triol Chemical class CCC(N)C(O)(O)O MCSJGXLZPITMIH-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- MHNNAWXXUZQSNM-UHFFFAOYSA-N 2-methylbut-1-ene Chemical compound CCC(C)=C MHNNAWXXUZQSNM-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- ZSFABVOIAIIPSQ-UHFFFAOYSA-N 3-ethylhept-1-yne Chemical group CCCCC(CC)C#C ZSFABVOIAIIPSQ-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BIDIHFPLDRSAMB-UHFFFAOYSA-N 4,4-dimethylpent-2-ene Chemical compound CC=CC(C)(C)C BIDIHFPLDRSAMB-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001436679 Adama Species 0.000 description 1
- VWVKUNOPTJGDOB-BDHVOXNPSA-N Anhydrous tofogliflozin Chemical compound C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 VWVKUNOPTJGDOB-BDHVOXNPSA-N 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101100114697 Danio rerio cpeb1 gene Proteins 0.000 description 1
- URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical class CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 241000927721 Tritia Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- WFYMOCDZCHGHHU-UONOGXRCSA-N [(1R,2S)-1-(2,5-difluorophenyl)-1-hydroxy-6,6-dimethylhept-4-yn-2-yl] carbamate Chemical compound C(N)(O[C@H]([C@H](O)C1=C(C=CC(=C1)F)F)CC#CC(C)(C)C)=O WFYMOCDZCHGHHU-UONOGXRCSA-N 0.000 description 1
- AHIBWURJLGCHAY-UHFFFAOYSA-N [S].C1=CC=CC=C1 Chemical compound [S].C1=CC=CC=C1 AHIBWURJLGCHAY-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N allylamine Natural products NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MVIOINXPSFUJEN-UHFFFAOYSA-N benzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=CC=C1 MVIOINXPSFUJEN-UHFFFAOYSA-N 0.000 description 1
- JAQPGQYDZJZOIN-LQDWTQKMSA-N benzylpenicillin benethamine Chemical class C=1C=CC=CC=1C[NH2+]CCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 JAQPGQYDZJZOIN-LQDWTQKMSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950010300 denagliptin Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- RVIMTVIYJAEION-UHFFFAOYSA-N dodec-4-yne Chemical compound CCCCCCCC#CCCC RVIMTVIYJAEION-UHFFFAOYSA-N 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 229950006535 ertugliflozin Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- KDXHMSSQTZYIIZ-UHFFFAOYSA-N ethyl 2-aminopent-4-ynoate Chemical compound CCOC(=O)C(N)CC#C KDXHMSSQTZYIIZ-UHFFFAOYSA-N 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 229950003707 farglitazar Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- USKZHEQYENVSMH-UHFFFAOYSA-N hepta-1,3,5-triene Chemical compound CC=CC=CC=C USKZHEQYENVSMH-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 102000045598 human DPP4 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229950000991 ipragliflozin Drugs 0.000 description 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950004397 luseogliflozin Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- QYZLKGVUSQXAMU-UHFFFAOYSA-N penta-1,4-diene Chemical compound C=CCC=C QYZLKGVUSQXAMU-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N piperylene Natural products CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RAGBYXLIHQFIPK-UHFFFAOYSA-N prop-2-ynyl benzenesulfonate Chemical compound C#CCOS(=O)(=O)C1=CC=CC=C1 RAGBYXLIHQFIPK-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 229940126844 remogliflozin Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- GBZKGWNNTNGFMD-XYOKQWHBSA-N tert-butyl (4E)-4-(dimethylaminomethylidene)-5-oxo-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate Chemical compound CN(C)\C=C/1\C(CC2CN(CC2\1)C(=O)OC(C)(C)C)=O GBZKGWNNTNGFMD-XYOKQWHBSA-N 0.000 description 1
- QNBHWCGDSUGOKS-UHFFFAOYSA-N tert-butyl 10-methyl-4,9,11-triazatricyclo[6.4.0.02,6]dodeca-1(12),8,10-triene-4-carboxylate Chemical compound CC1=NC=C2C3CN(CC3CC2=N1)C(=O)OC(C)(C)C QNBHWCGDSUGOKS-UHFFFAOYSA-N 0.000 description 1
- SCZITRKEHNGPBE-UHFFFAOYSA-N tert-butyl 4-(2-trimethylsilylethoxymethyl)-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2,5-diene-10-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC3=NN(C=C3C2C1)COCC[Si](C)(C)C SCZITRKEHNGPBE-UHFFFAOYSA-N 0.000 description 1
- GGNDIMLSSMWKDR-UHFFFAOYSA-N tert-butyl 5-oxo-1,3,3a,4,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate Chemical compound C1C(=O)CC2CN(C(=O)OC(C)(C)C)CC21 GGNDIMLSSMWKDR-UHFFFAOYSA-N 0.000 description 1
- LAMJKHOFLTXAGD-UHFFFAOYSA-N tert-butyl 5-oxo-4-(2,2,2-trifluoroacetyl)-1,3,3a,4,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC(=O)C(C2C1)C(=O)C(F)(F)F LAMJKHOFLTXAGD-UHFFFAOYSA-N 0.000 description 1
- JHRXIEDMQJNOTL-UHFFFAOYSA-N tert-butyl N-(6-methoxy-5-oxohept-1-yn-4-yl)carbamate Chemical compound CC(C(=O)C(CC#C)NC(=O)OC(C)(C)C)OC JHRXIEDMQJNOTL-UHFFFAOYSA-N 0.000 description 1
- YMDVBHAWLZJGST-ICHXDWOFSA-N tert-butyl N-[(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl)oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C=NN5 YMDVBHAWLZJGST-ICHXDWOFSA-N 0.000 description 1
- ZQHBDTIGTAHVPE-PDRSGWLNSA-N tert-butyl N-[(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[3-(trifluoromethyl)-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl]oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C(=NN5)C(F)(F)F ZQHBDTIGTAHVPE-PDRSGWLNSA-N 0.000 description 1
- BKSUOSLLNFDVDU-NULJUDJWSA-N tert-butyl N-[(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[5-(2-hydroxyethyl)-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl]oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C=NN5CCO BKSUOSLLNFDVDU-NULJUDJWSA-N 0.000 description 1
- QZJCJYVRLIIBHV-ALPTYBBSSA-N tert-butyl N-[(2R,3S,5R)-5-(3-carbamoyl-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl)-2-(2,5-difluorophenyl)oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C(=NN5)C(=O)N QZJCJYVRLIIBHV-ALPTYBBSSA-N 0.000 description 1
- VWCUIFTXCOIXTG-JCEZOZDFSA-N tert-butyl N-[(2R,3S,5R)-5-(4-cyclopropylsulfonyl-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2,5-dien-10-yl)-2-(2,5-difluorophenyl)oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=NN(C=C5C4C3)S(=O)(=O)C6CC6 VWCUIFTXCOIXTG-JCEZOZDFSA-N 0.000 description 1
- JDTQCBSPAOMEHJ-FYUZZUMWSA-N tert-butyl N-[(2R,3S,5R)-5-(5-cyclopropylsulfonyl-4,5,10-triazatricyclo[6.3.0.02,6]undeca-2(6),3-dien-10-yl)-2-(2,5-difluorophenyl)oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@H](CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CC4CC5=C(C4C3)C=NN5S(=O)(=O)C6CC6 JDTQCBSPAOMEHJ-FYUZZUMWSA-N 0.000 description 1
- OLXPRJZWYJVTID-UONOGXRCSA-N tert-butyl n-[(2r,3s)-2-(2,5-difluorophenyl)-3,4-dihydro-2h-pyran-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CC=CO[C@@H]1C1=CC(F)=CC=C1F OLXPRJZWYJVTID-UONOGXRCSA-N 0.000 description 1
- RYDSJJXCDQFTKF-INPHSSGZSA-N tert-butyl n-[(2r,3s)-2-(2,5-difluorophenyl)-5-hydroxyoxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CC(O)CO[C@@H]1C1=CC(F)=CC=C1F RYDSJJXCDQFTKF-INPHSSGZSA-N 0.000 description 1
- FCPUEOMVOKWZQD-UHFFFAOYSA-N tert-butyl n-[1-(2,5-difluorophenyl)-1-oxopent-4-yn-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CC#C)C(=O)C1=CC(F)=CC=C1F FCPUEOMVOKWZQD-UHFFFAOYSA-N 0.000 description 1
- JJOBBHMBMRQQHU-UHFFFAOYSA-N tert-butyl n-prop-2-enyl-n-prop-2-ynylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC=C)CC#C JJOBBHMBMRQQHU-UHFFFAOYSA-N 0.000 description 1
- KTQKOGBTMNDCFG-UHFFFAOYSA-N tert-butyl(diphenyl)silicon Chemical compound C=1C=CC=CC=1[Si](C(C)(C)C)C1=CC=CC=C1 KTQKOGBTMNDCFG-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229950006667 tofogliflozin Drugs 0.000 description 1
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 1
- 229950010728 trelagliptin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical class CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- SDTYFWAQLSIEBH-UHFFFAOYSA-N undec-3-ene Chemical compound CCCCCCCC=CCC SDTYFWAQLSIEBH-UHFFFAOYSA-N 0.000 description 1
- DPWGJNPCPLQVKQ-UHFFFAOYSA-N undec-3-yne Chemical compound CCCCCCCC#CCC DPWGJNPCPLQVKQ-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of ternarys to condense cyclosubstituted amino hexatomic ring analog derivative and its application in medicine, in particular to ternary shown in logical formula (I) condense cyclosubstituted amino hexatomic ring analog derivative or its stereoisomer, pharmaceutically acceptable salt, prodrug, the pharmaceutical composition containing the derivative and in the purposes pharmaceutically for preparing DPP IV (DPP-IV) inhibitor, formula of (I) definition of each substituent group it is identical as the definition of specification.
Description
Technical field
The present invention relates to a kind of ternarys to condense cyclosubstituted amino hexatomic ring analog derivative and its application in medicine, tool
Body, which is said, is related to that ternary shown in logical formula (I) condenses cyclosubstituted amino hexatomic ring analog derivative or medicinal salt can be used for it or it is three-dimensional
Isomers and pharmaceutical composition containing the derivative as well as therapeutic agent are especially as DPP IV (DPP-
IV) the purposes of inhibitor.
Background technique
Diabetes are a worldwide great medical care problems, are counted according to International Diabetes Federation (IDF), 2013
Up to 3.82 hundred million, global medical is spent up to 548,000,000,000 dollars global diabetic's number, accounts for the 11% of global medical expenditure.In advance
It counts by 2035, global medical cost relevant to diabetes is up to 627,300,000,000 dollars.Insulin be by sucrose, starch and its
His food conversion hormone required when being energy, diabetes be often as cannot secreting from body or suitably using insulin and
It is caused.It is (or non-that diabetes are typically divided into type-1 diabetes mellitus (or insulin-dependent diabetes mellitus, IDDM) and type II diabetes
Insulin-dependent diabetes mellitus, NIDDM).The most common diabetes type is type II diabetes, worldwide, II type sugar
Urine disease accounts for about the 90% of all diabetes.Due to modern unsound life style, such as exercise reduces and high caloric diet is former
Cause, the disease incidence of type II diabetes are in the trend gradually increased.Huge market potential has attracted a large amount of drugmaker and has ground
Study carefully center and develops new anti-diabetic target spot and drug.
The drug for treating type II diabetes listing of approved mainly has insulin and the like, sulfonylureas at present
Class, biguanides, thiazolidinediones (TZDs), alpha-glucosidase restrainer, dextrin analog, gut incretin hormones are similar
Object, depeptidyl peptidase inhibitors (DPP-IV) etc..However, patient, which takes these antidiabetic drugs for a long time, cannot still reach expected saccharification
Hemoglobin (HbA1c) reduces index, and these antidiabetic drugs have side effect, such as hypoglycemia, weight gain and painstaking effort manage-style
Danger etc..These side effects have aggravated the burden of diabetic.Therefore, there is an urgent need to have height for type II diabetes exploitation
The novel antidiabetic drug of effect, few side effects.
DPP IV (Dipeptidyl Peptidase, DPP-IV, EC3.4.14.5) is a serine stretch protein
Enzyme, from the polypeptide N-terminal penultimate hydrolyzing N end dipeptides containing L-PROLINE and l-Alanine.Although the function of DPP-IV is not
Be fully elucidated, it be considered as certain adjusting polypeptides, neuropeptide, circulating hormone and chemotactic factor (CF) major physiologicals adjust because
Son.Although DPP-IV has many substrates as multiple-effect enzyme, that most known is secretin, it includes glucagon
Sample peptide -1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).Secretin is a few minutes endocrine in intake nutrients
And promote to take in the enteron aisle hormone of the disposition of nutrients.GLP-1 and GIP is identical to the effect of β cell, can improve β cell function,
Insulin secretion, inducing beta cell proliferation, enhancing Anti-G value (Diabetes and including promoting dependence on the glucose
Vascular Disease Research 20063:159)。
Different from GIP, GLP-1 is still to promote insulin secretion in type II diabetes, and therefore, improving GLP-1 is one
The means (Pharmacol Rev 60:470-512,2008) of the promising treatment type II diabetes of kind.Patients with NIDDM
It is middle to can obviously reduce blood glucose (Lancet, 2002,359:824-830) using GLP-1, however substrate of the GLP-1 as DPP-IV
It can be hydrolyzed rapidly and inactivate in vivo, therefore develop DPP-IV inhibitor and have very important significance to treatment diabetes.
Currently, the research of DPP-IV inhibitor makes great progress, including sitagliptin, saxagliptin, A Gelie
DPP-IV inhibitor including spit of fland has been approved by listing.The most significant feature of DPP-IV inhibitor is, due to incretin
It is secreted after body feed, DPP-IV inhibitor is not easy to increase insulin level when unsuitable, generates many antidiabetic drugs
Common side effect hypoglycemia.Recent clinical data reduces blood it has been shown that DPP-IV is inhibited insulin secretion can be made to increase
Sugared concentration simultaneously improves pancreas islet beta cell function (Diabetes, 1998,47:1253-1258).Common DPP-IV inhibitor
Side effect has respiratory tract infection, sore throat, diarrhea, cold like symptoms, headache and dizzy etc..But it is overall have preferable safety and
Tolerance, the patient used there is presently no discovery have serious weight gain or the diseases such as potential weight loss and oedema
Shape.
The disease incidence of diabetes (mainly type II diabetes) is in increase trend year by year in the world, is become after painstaking effort
After pipe disease and tumour, the 3rd threatens the non-communicable diseases of health of people and life.The treatment of diabetes is to family and society
Heavy burden can be brought.Therefore, urgent need exploitation more updates better DPP-IV inhibition drug and is faced with meeting many patients
The needs of bed medication.
Currently, the document about DPP-IV inhibitor correlative study is reported in succession:
(1) WO2008060488 discloses the compound such as flowering structure as DPP-IV inhibitor,
Wherein:
Ar, which is selected from, is selected from halogen, hydroxyl, C by 1-51-6The phenyl that the substituent groups such as alkyl replace;
X is selected from O or CH2;
V is selected fromEqual groups;It is not considered as to specifically describe in this patent
It is a part of the invention.
(2) US20100120863 discloses the compound such as flowering structure as DPP IV (DPP-IV) inhibitor,
Treatment, prevention type-2 diabetes mellitus purposes,
Wherein:
Ra is selected from the groups such as hydrogen, alkyl;V is selected fromDeng, and R3a、R3bSelected from independently selecting
From hydrogen, the C replaced by 1-5 fluorine atom1-4Alkyl;R2Selected from groups such as hydrogen, hydroxyl, halogen, carboxyls;R8Selected from-S (O)2-C1-6
Naphthenic base ,-S (O)2-C1-6The groups such as alkyl;It is not considered as that specifically describing in this patent is a part of the invention.
(3) CN102272136, which discloses the compound of flowering structure such as, has DPP-IV inhibitor effect, as diabetes
The purposes of prevention and/or medicine,
Wherein:
Ar is the phenyl optionally replaced by 1-5 independently selected from groups such as halogen, cyano, hydroxyls;
V is selected fromEqual groups, and R2Selected from groups such as hydrogen, cyano, halogen, alkyl, carbonyls;
R3a、R3bThe C selected from hydrogen or optionally replaced by 1-5 fluorine atom1-4Alkyl;R8It is selected from ,-SO2-C1-6The groups such as alkyl;It is not considered as
Specifically describing in this patent is a part of the invention.
(4) compound that WO2007097931 discloses DPP-IV inhibitor such as flowering structure is used to treat diabetes,
Wherein:
Ar is selected from substituted or unsubstituted phenyl, and when replacing, phenyl is selected from halogen, hydroxyl, C by 1-31-6Alkyl etc.
Replace;
V is selected fromEqual groups, and R2 is selected from hydrogen, hydroxyl, halogen etc.;R3a、R3bSelected from hydrogen,
The C replaced by 1-5 fluorine atom1-4Alkyl;It is not considered as that specifically describing in this patent is a part of the invention.
There are also WO2011103256, WO2008060488, WO2007087231, WO2011037793, WO2011028455,
WO2009025784 etc. also discloses related DPP-IV inhibitor compound for treating diabetes.
The purpose of the present invention is introducing a kind of novel DPP-IV inhibitors, specifically there is chemical combination shown in logical formula (I)
Object, research has shown that, the compound of this class formation has good DPP IV (DPP-IV) inhibitory activity and selectivity,
With the prospect for treating or alleviating type-2 diabetes mellitus and similar disease.
Summary of the invention
Cyclosubstituted amino hexatomic ring analog derivative is condensed the present invention relates to ternary shown in a kind of logical formula (I) or it is three-dimensional
Isomers, pharmaceutically acceptable salt or prodrug:
Wherein:
X is selected from-O- ,-S- ,-NH- or-CH2, preferably-O-;
W is selected from
R1、R1a、R1b、R1cAnd R1dIt is each independently selected from H, F, Cl, Br, I, cyano, hydroxyl, C1-8Alkyl, C1-8Alcoxyl
Base, the alkyl or alkoxy are optionally further replaced the substituent group of 0 to 5 F, Cl, Br, I, cyano, amino or hydroxyl;
R1、R1a、R1b、R1cAnd R1dRespectively independent preferably H, F, Cl, Br, C1-2Alkyl or C1-2Alkoxy;R1、R1a、R1b、R1cAnd R1dRespectively
Independent further preferably H or F;
R2Selected from H, C1-8Alkyl ,-(CH2)m- S (=O)n-C1-8Alkyl ,-(CH2)m- S (=O)n-C3-8Naphthenic base ,-
(CH2)m- S (=O)n(3 to 8 circle heterocyclic ring base) ,-(CH2)m- S (=O)n-C6-14Aryl ,-(CH2)m- S (=O)n(6 to 14 yuan
Heteroaryl) ,-(CH2)m- C (=O)-OH ,-(CH2)m- C (=O)-C1-8Alkyl ,-(CH2)m- C (=O)-O-C1-8Alkyl ,-
(CH2)m- C (=O)-C3-8Naphthenic base ,-(CH2)m- C (=O)-O-C3-8Naphthenic base or-(CH2)m- C (=O)-NR7R8, wherein institute
Alkyl, naphthenic base, heterocycle, aryl or heteroaryl are stated optionally further by 0 to 5 F, Cl, Br, I ,-CH2F、-CHF2、-CF3、
Hydroxyl, C1-8Alkyl, C1-8Alkoxy, C3-8Replaced the substituent group of naphthenic base or 3 to 8 circle heterocyclic ring bases;The heterocycle or miscellaneous
Aryl contains 1 to 5 selected from N, O or S (=O)nAtom or group;R2It is preferred that H, C1-4Alkyl ,-(CH2)m- S (=O)n-C1-4
Alkyl ,-(CH2)m- S (=O)n-C3-6Naphthenic base ,-(CH2)m- S (=O)n(3 to 8 circle heterocyclic ring base) ,-(CH2)m- C (=O)-O-
C1-4Alkyl or-(CH2)m- C (=O)-NR7R8, wherein the alkyl, naphthenic base or heterocycle optionally further by 0 to 3 F,
Cl、Br、I、-CH2F、-CHF2、-CF3, hydroxyl, C1-2Alkyl or C1-2Replaced the substituent group of alkoxy, the heterocycle contains
There is 1 to 3 to be selected from N, O or S (=O)nAtom or group;R2Further preferred H, C1-4Alkyl ,-S (=O)2-C1-4Alkyl or-
(CH2)m- S (=O)2-C3-6Naphthenic base, wherein the alkyl or cycloalkyl is optionally further by 0 to 3 F, Cl, Br ,-CH2F、-
CHF2、-CF3Or replaced the substituent group of hydroxyl;R2More preferable H, methyl, ethyl, propyl,
R3Selected from H, F, Cl, Br, I, hydroxyl, cyano, C1-8Alkyl, C1-8Alkoxy ,-(CH2)m-C2-8Alkenyl-R5、-
(CH2)m-C2-8Alkynyl-R5、-(CH2)m- C (=O)-R6、-(CH2)m- C (=O)-OR6、-(CH2)m-C3-8Naphthenic base ,-(CH2)m-
(3 to 8 circle heterocyclic ring base) ,-(CH2)m-C6-14Aryl ,-(CH2)m(6 to 14 unit's heteroaryl) ,-(CH2)m-NR7R8、-(CH2)m-C
(=O)-NR7R8、-(CH2)m- O-C (=O)-NR7R8、-(CH2)m- S (=O)n-R9、-(CH2)m-NR10C (=O)-NR7R8、-
(CH2)m-NR10C (=O)-R6Or-(CH2)m-NR10C (=O)-OR6, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkanes
Base, heterocycle, aryl or heteroaryl are optionally further selected from F, Cl, Br, I ,-CH by 0 to 52F、-CHF2、-CF3, cyano, nitre
Base, isocyano group, hydroxyl, aldehyde radical, carboxyl, C1-8Alkyl or C1-8Replaced the substituent group of alkoxy, wherein (CH2)mIn it is any
CH2Hydrogen atom is optionally by 0 to 2 independently selected from F, hydroxyl ,-CH2F、-CHF2、-CF3、C1-4Alkyl or C1-4Alkoxy takes
Replaced Dai Ji;R3It is preferred that H, F, Cl, Br, hydroxyl, cyano, C1-4Alkyl ,-(CH2)m- C (=O)-R6、-(CH2)m- C (=O)-
NR7R8Or-(CH2)m- S (=O)n-R9, wherein the alkyl is optionally further selected from F, Cl, Br ,-CH by 0 to 32F、-
CHF2、-CF3Or replaced the substituent group of hydroxyl;R3Further preferred H, F, cyano, C1-4Alkyl ,-(CH2)m- C (=O)-R6Or-
(CH2)m- C (=O)-NR7R8, wherein the alkyl is optionally further selected from F, Cl, Br ,-CH by 0 to 32F、-CHF2、-CF3
Or replaced the substituent group of hydroxyl;R3More preferable R3Selected from H, methyl, ethyl ,-CF3、
R4Selected from H, F, Cl, Br, I, C1-8Alkyl or C3-8Naphthenic base, wherein the alkyl or cycloalkyl optionally further by
0 to 5 is selected from F, Cl, Br, I ,-CH2F、-CHF2、-CF3Or replaced the substituent group of hydroxyl;R4It is preferred that H, F, C1-8Alkyl or
C3-8Naphthenic base, wherein the alkyl or cycloalkyl is optionally further selected from replaced the substituent group of F, Cl or hydroxyl by 0 to 3;
R4More preferable methyl ,-CF3Or
R5And R6It is each independently selected from H, amino, hydroxyl, C1-8Alkyl, C1-8Alkoxy, C3-8Naphthenic base or 3 to 8 yuan it is miscellaneous
Ring group, the heterocycle contain 1 to 5 selected from N, O or S (=O)nAtom or group;R5And R6Respectively independent preferably H, ammonia
Base, hydroxyl, C1-4Alkyl or C1-4Alkoxy;
R7、R8And R10It is each independently selected from H, C1-8Alkyl or C3-8Naphthenic base, wherein the alkyl or cycloalkyl is optional
Further replaced by the substituent group of 0 to 5 F, Cl, Br, I, hydroxyl, cyano, amino or nitro;R7、R8And R10It is respectively independent excellent
Select H or C1-4Alkyl;R7And R8Respectively independent further preferably H or C1-2Alkyl;
R9Selected from H, C1-8Alkyl, C3-8Naphthenic base or 3 to 8 circle heterocyclic ring bases, the heterocycle contain 1 to 5 selected from N, O
Or S (=O)nAtom or group;R9It is preferred that C1-4Alkyl;R9Further preferred C1-2Alkyl;
N is selected from 0,1 or 2;N preferably 2;
M is selected from 0,1,2,3 or 4;M preferably 0 or 1.
The preferred solution of the invention, including ternary shown in logical formula (I) condense cyclosubstituted amino hexatomic ring analog derivative or its
Stereoisomer, pharmaceutically acceptable salt or prodrug, in which:
X is selected from-O-;
W is selected from
R1、R1a、R1b、R1cAnd R1dIt is each independently selected from H, F, Cl, Br, C1-2Alkyl or C1-2Alkoxy;R1、R1a、R1b、
R1cAnd R1dRespectively independent preferably H or F;Further preferably, R1And R1cIt is each independently selected from H, R1aAnd R1dF is each independently selected from,
R1bSelected from H or F;
R2Selected from H, C1-4Alkyl ,-(CH2)m- S (=O)n-C1-4Alkyl ,-(CH2)m- S (=O)n-C3-6Naphthenic base ,-
(CH2)m- S (=O)n(3 to 8 circle heterocyclic ring base) ,-(CH2)m- C (=O)-O-C1-4Alkyl or-(CH2)m- C (=O)-NR7R8,
Described in alkyl, naphthenic base or heterocycle optionally further by 0 to 3 F, Cl, Br, I ,-CH2F、-CHF2、-CF3, hydroxyl, C1-2
Alkyl or C1-2Replaced the substituent group of alkoxy;The heterocycle contains 1 to 3 selected from N, O or S (=O)nAtom or
Group;R2It is preferred that H, C1-4Alkyl ,-(CH2)m- S (=O)n-C1-4Alkyl or-(CH2)m- S (=O)n-C3-6Naphthenic base, wherein institute
Alkyl or cycloalkyl is stated optionally further replaced the substituent group of 0 to 3 F, Cl, Br or hydroxyl;
R3Selected from H, F, Cl, Br, hydroxyl, cyano, C1-4Alkyl ,-(CH2)m- C (=O)-R6、-(CH2)m- C (=O)-
NR7R8Or-(CH2)m- S (=O)n-R9, wherein the alkyl is optionally further selected from F, Cl, Br ,-CH by 0 to 32F、-
CHF2、-CF3Or replaced the substituent group of hydroxyl;R3It is preferred that H, F, Cl, Br, hydroxyl, cyano, C1-4Alkyl ,-(CH2)m- C (=O)-
R6Or-(CH2)m- C (=O)-NR7R8, wherein the alkyl optionally further substitution by 0 to 3 selected from F, Cl, Br or hydroxyl
Replaced base;
R4Selected from H, F, C1-4Alkyl or C3-6Naphthenic base, wherein the alkyl or cycloalkyl is optionally further selected by 0 to 3
Replaced the substituent group of F, Cl, Br or hydroxyl;R4It is preferred that H, C1-4Alkyl or C3-6Naphthenic base, wherein the alkyl or cycloalkyl
Optionally further replaced 0 to 3 substituent group selected from F, Cl, Br;
R6Independently selected from amino, hydroxyl, C1-4Alkyl or C1-4Alkoxy;R6It is preferred that C1-4Alkoxy, further preferred C1-2
Alkoxy;
R7And R8It is each independently selected from H or C1-4Alkyl;R7And R8Respectively independent preferably H or C1-2Alkyl;
R9Selected from C1-4Alkyl, C3-6Naphthenic base or 3 to 6 circle heterocyclic ring bases, the heterocycle contain 1 to 3 selected from N, O or
S (=O)nAtom or group;R9Preferential C1-4Alkyl, further preferred C1-2Alkyl;
N is selected from 0,1 or 2;N preferably 2;
M is selected from 0,1 or 2;M preferably 0 or 1.
The preferred solution of the invention, including ternary shown in logical formula (I) condense cyclosubstituted amino hexatomic ring analog derivative or its
Stereoisomer, pharmaceutically acceptable salt or prodrug, in which:
R1、R1a、R1b、R1cAnd R1dIt is each independently selected from H, F, Cl, Br, methyl, ethyl, methoxy or ethoxy;R1With
R1cIt is preferred that H, R1aAnd R1dIt is preferred that F, R1bIt is preferred that H or F;
R2Selected from H, C1-4Alkyl ,-(CH2)m- S (=O)n-C1-4Alkyl ,-(CH2)m- S (=O)n-C3-6Naphthenic base ,-
(CH2)m- C (=O)-O-C1-4Alkyl or-(CH2)m- C (=O)-NR7R8, wherein the alkyl or cycloalkyl is optionally further by 0
To 3 F, Cl, Br ,-CH2F、-CHF2、-CF3Or replaced the substituent group of hydroxyl;R2It is preferred that H, C1-4Alkyl ,-(CH2)m- S (=
O)n-C1-4Alkyl ,-(CH2)m- S (=O)n-C3-6Naphthenic base, wherein the alkyl or cycloalkyl optionally further by 0 to 3 F,
Cl、Br、-CH2F、-CHF2、-CF3Or replaced the substituent group of hydroxyl;R2Further preferred H, C1-2Alkyl ,-(CH2)m- S (=
O)n-C1-2Alkyl ,-(CH2)m- S (=O)n-C3-6Naphthenic base, wherein the alkyl or cycloalkyl optionally further by 0 to 3 F,
Replaced the substituent group of Cl, Br or hydroxyl;R2Still more preferably H, methyl, ethyl, propyl,R2More preferable H,
R3Selected from H, F, cyano, C1-4Alkyl ,-(CH2)m- C (=O)-R6、-(CH2)m- C (=O)-NR7R8Or-(CH2)m-S
(=O)n-R9, wherein the alkyl is optionally further selected from F, Cl, Br ,-CH by 0 to 32F、-CHF2、-CF3Or hydroxyl takes
Replaced Dai Ji;R3It is preferred that H, C1-4Alkyl ,-C (=O)-R6Or-C (=O)-NR7R8, wherein the alkyl is optionally further by 0
F, Cl, Br ,-CH are selected to 32F、-CHF2、-CF3Or replaced the substituent group of hydroxyl;R3Further preferred H, methyl, second
Base ,-CF3、R3More preferable H ,-CF3、
R4Selected from H, C1-4Alkyl or C3-6Naphthenic base, wherein the alkyl or cycloalkyl is optionally further selected from by 0 to 3
F, replaced the substituent group of Cl, Br or hydroxyl;R4It is preferred that H, C1-2Alkyl or C3-6Naphthenic base, wherein the alkyl or cycloalkyl is appointed
Choosing is further replaced 0 to 3 substituent group selected from F, Cl, Br or hydroxyl;R4More preferable methyl ,-CF3Or
R6Selected from amino, hydroxyl or C1-4Alkoxy;R6It is preferred that amino, hydroxyl or C1-2Alkoxy;R6Further preferred C1-2
Alkoxy;
R7And R8It is each independently selected from H or C1-4Alkyl;R7And R8Respectively independent preferably H or C1-2Alkyl;
R9Selected from C1-4Alkyl;R9It is preferred that C1-2Alkyl;
N is selected from 2;
M is selected from 0,1 or 2;M preferably 0.
The preferred solution of the invention, including ternary shown in logical formula (I) condense cyclosubstituted amino hexatomic ring analog derivative or its
Stereoisomer, pharmaceutically acceptable salt or prodrug, in which:
R1、R1a、R1b、R1cAnd R1dIt is each independently selected from H or F;R1And R1cIt is preferred that H, R1aAnd R1dIt is preferred that F, R1bIt is preferred that H or
F;
R2Selected from H, C1-4Alkyl ,-S (=O)2-C1-4Alkyl or-S (=O)2-C3-6Naphthenic base, wherein the alkyl or ring
Alkyl is optionally further by 0 to 3 F, Cl, Br ,-CH2F、-CHF2、-CF3Or replaced the substituent group of hydroxyl;R2It is preferred that H, C1-2
Alkyl ,-S (=O)2-C1-2Alkyl or-S (=O)2-C3-6Naphthenic base, wherein the alkyl or cycloalkyl is optionally further by 0 to 3
Replaced the substituent group of a F, Cl, Br or hydroxyl;
R3Selected from H, C1-4Alkyl ,-C (=O)-R6Or-C (=O)-NR7R8, wherein the alkyl is optionally further by 0 to 3
It is a to be selected from F, Cl, Br ,-CH2F、-CHF2、-CF3Or replaced the substituent group of hydroxyl;R3It is preferred that H, C1-2Alkyl ,-C (=O)-R6
Or-C (=O)-NR7R8, wherein the alkyl is optionally further selected from replaced the substituent group of F, Cl, Br or hydroxyl by 0 to 3;
R3Further preferred H, methyl, ethyl ,-CF3、R3More preferable H ,-CF3、
R4Selected from H, C1-4Alkyl or C3-6Naphthenic base, wherein the alkyl or cycloalkyl is optionally further selected from by 0 to 3
F, replaced the substituent group of Cl, Br or hydroxyl;R4It is preferred that H, C1-2Alkyl or C3-6Naphthenic base, wherein the alkyl or cycloalkyl is appointed
Choosing is further replaced 0 to 3 substituent group selected from F, Cl, Br or hydroxyl;
R6Selected from C1-4Alkoxy;R6It is preferred that C1-2Alkoxy;
R7And R8It is each independently selected from H or C1-4Alkyl;R7And R8Respectively independent preferably H or C1-2Alkyl;
The preferred solution of the invention, including ternary shown in logical formula (I) condense cyclosubstituted amino hexatomic ring analog derivative or its
Stereoisomer, pharmaceutically acceptable salt or prodrug, in which:
R1And R1cSelected from H, R1aAnd R1dSelected from F, R1bSelected from H or F;
R2Selected from H, methyl, ethyl, propyl,
R3Selected from H, methyl, ethyl ,-CF3、
R4Selected from methyl ,-CF3Or
The preferred solution of the invention, the present invention relates to compounds to be selected from, but is not limited to:
The invention further relates to compound shown in logical formula (I) or its stereoisomer, hydrate, solvate, pharmaceutically may be used
Salt, eutectic or the prodrug of receiving, wherein the salt include but is not limited to sodium salt, sylvite, calcium salt, magnesium salts, barium salt, ammonium salt,
Front three amine salt, triethylamine salt, pyridiniujm, picoline salt, 2,6- lutidines salt, ethanolamine salt, diethanolamine salt, three second
Alcohol amine salt, cyclohexylamine salt, dicyclohexyl ammonium salt, hydrochloride, hydrobromate, sulfate, nitrate, phosphate, formates, trifluoro
Acetate, acetate, maleate, tartrate, citrate, succinate, mandelate, fumarate, malonate,
Malate, 2 hydroxy propanoic acid salt, oxalates, oxyacetate, salicylate, glucuronate salt, galacturonic hydrochlorate, citron
Hydrochlorate, aspartate, glutamate, benzoate, cinnamate, tosilate, benzene sulfonate, mesylate, second
Sulfonate, fluoroform sulphonate or their combination.
The invention further relates to a kind of pharmaceutical composition, the composition includes ternary shown in the logical formula (I) of effective dose
Condense cyclosubstituted amino hexatomic ring analog derivative or its stereoisomer, pharmaceutically acceptable salt or prodrug and/or one kind
Or various other therapeutic agents and pharmaceutically acceptable carrier or excipient.
The invention further relates to a kind of pharmaceutical compositions, wherein the other therapeutic agents include:
(a) DPP-IV inhibitor or pharmaceutically acceptable salt, and/or
(b) SGLT-2 inhibitor or pharmaceutically acceptable salt, and/or
(c) biguanides, thiazolidinediones, sulfonylurea, column how class, alpha-glucosidase restrainer or glucagon
- 1 analog of sample peptide or its pharmaceutically acceptable salt or prodrug.
Composition of the present invention, wherein the SGLT-2 inhibitor is selected from Dapagliflozin, canagliflozin, A Gelie
Only, En Palie is net, Yi Palie is net, Tuo Fulie is net, Lu Silie is net, Rui Gelie is net, Sergliflozin or support column are net;DPP-IV inhibits
Agent be selected from BI 1356, sitagliptin, vildagliptin, Egelieting, saxagliptin, Na Lieting, carmegliptin, mage column
Ge Lieting, gigue column spit of fland or song Ge Lieting, are replaced at dutogliptin in spit of fland;Biguanides therapeutic agent is selected from melbine or insoral;Thiophene
Oxazolidinedione class therapeutic agent is selected from Ciglitazone, pioglitazone, Rosiglitazone, troglitazone, Fa Gelie ketone or Darglitazone, sulphur
Ureide derivative therapeutic agent is selected from Glimepiride, orinase, Glibornuride, glibenclamide, gliquidone, Glipizide or lattice column
Qi Te, how class therapeutic agent is selected from Nateglinide, Repaglinide or Mitiglinide to column, and alpha-glucosidase restrainer is selected from A Kabo
Sugar, voglibose or Miglitol, glucagon-like peptide-1 analogs are selected from Exenatide or Liraglutide.
The invention further relates to compound described in logical formula (I) or its stereoisomers, pharmaceutically acceptable salt and its group
It closes object or its prodrug is preparing the application in dipeptidyl peptidase-iv inhibitor, wherein the dipeptidyl peptidase-iv inhibitor is used
In the drug of preparation treatment metabolic disease, wherein the metabolic disease is selected from diabetes, diabetic retinopathy, sugar
Urinate the raised of characteristic of disease neuropathy, nephrosis, insulin resistance, hyperglycemia, hyperinsulinemia, fatty acid or glycerol
Level, hyperlipidemia, obesity, Hypertriglyceridemia, X syndrome, diabetic complication, atherosclerosis or high blood
Pressure;Preferably, the diabetes are type-2 diabetes mellitus.
Unless there are opposite statement, the term used in the specification and in the claims has following meanings.
Carbon, hydrogen, oxygen, sulphur, nitrogen or halogen involved in group and compound of the present invention include their same position
Carbon, hydrogen, oxygen, sulphur, nitrogen or halogen involved in element and group of the present invention and compound are optionally further by one or more
Their a corresponding isotopes are substituted, and wherein the isotope of carbon includes12C、13C and14C, the isotope of hydrogen include protium (H), deuterium
(D, also known as heavy hydrogen), tritium (T, also known as superheavy hydrogen), the isotope of oxygen include16O、17O and18The isotope of O, sulphur includes32S
、33S、34S and36The isotope of S, nitrogen includes14N and15N, the isotope of fluorine19The isotope of F, chlorine includes35Cl and37Cl, bromine it is same
Position element include79Br and81Br。
" alkyl " refers to the saturated aliphatic hydrocarbons group of straight chain and branch, and main chain includes 1 to 20 carbon atom, preferably 1
To 12 carbon atoms, further preferably 1 to 8 carbon atom, more preferably 1 to 6 carbon atom, still further preferably 1 to 4
The straight chain and branched group of carbon atom, most preferably 1 to 2 carbon atom.The example of alkyl includes but is not limited to methyl, ethyl, just
Propyl, isopropyl, normal-butyl, isobutyl group, sec-butyl, tert-butyl, n-pentyl, 2- amyl, 3- amyl, 2- methyl -2- butyl, 3-
Methyl-2- butyl, 3- methyl-1-butyl, 2-methyl-1-butene base, n-hexyl, 2- hexyl, 3- hexyl, 2- methyl-2- amyl, 3-
Methyl -2- amyl, 4- methyl -2- amyl, 3- methyl -3- amyl, 2- methyl -3- amyl, 2,3- dimethyl -2- butyl, 3,3-
Dimethyl -2- butyl, n-heptyl, 2- methylhexyl, 3- methylhexyl, 4- methylhexyl, 5- methylhexyl, 2,2- dimethyl-penten
Base, 2,3- dimethyl amyl group, 2,4- dimethyl amyl group, 3,3- dimethyl amyl group, 2- ethylpentyl, 3- ethylpentyl, n-octyl,
2,2- dimethylhexanyl, 2,3- dimethylhexanyl, 2,4- dimethylhexanyl, 2,5- dimethylhexanyl, 3,3- dimethylhexanyl, 4,
4- dimethylhexanyl, 2- ethylhexyl, 3- ethylhexyl, 4- ethylhexyl, 2- methyl -2- ethylpentyl, 2- methyl -3- ethyl
Amyl, n-nonyl, 2- methyl -2- ethylhexyl and positive decyl etc..Alkyl can be substituted or unsubstituted, when substituted
When, substituent group can be substituted on any workable tie point, and substituent group is preferably 1 to 5 selected from F, Cl, Br, I, alkane
It is base, naphthenic base, alkoxy, halogenated alkyl, mercaptan, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, aryl, heteroaryl, miscellaneous
Ring group, bridged ring base, loop coil base and ring group, hydroxy alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=O)-Ra、-
O-(CH2)m- C (=O)-Ra、-(CH2)m- C (=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、ORdOr-
(CH2)mAlkynyl-Ra(wherein 0,1 or 2 m, n), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith RcIt is independent
Selected from including H, hydroxyl, amino, carbonyl, alkyl, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl, fluoroform
Sulfonyl, it is alternatively that, RbWith RcFive or hexa-atomic naphthenic base or heterocycle can be formed.RaWith RdIt is each independently selected from aryl, heteroaryl
Base, alkyl, alkoxy, naphthenic base, heterocycle, carbonyl, ester group, bridged ring base, loop coil base and ring group.
" alkoxy " refers to-O- alkyl, wherein for example hereinbefore definition of alkyl.Alkoxy can be substituted or unsubstituted
, alkoxy embodiment include but is not limited to methoxyl group, ethyoxyl, positive propoxy, isopropoxy, n-butoxy, isobutoxy,
Tert-butoxy, sec-butoxy, n-pentyloxy and positive hexyloxy etc..When substituted, substituent group be preferably 1 to 5 selected from F, Cl,
It is Br, I, alkyl, naphthenic base, alkoxy, halogenated alkyl, mercaptan, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, aryl, miscellaneous
Aryl, heterocycle, bridged ring base, loop coil base and ring group, hydroxy alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=
O)-Ra、-O-(CH2)m- C (=O)-Ra、-(CH2)m- C (=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、
ORdOr-(CH2)mAlkynyl-Ra(wherein 0,1 or 2 m, n), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith
RcBe independently selected from including H, hydroxyl, amino, carbonyl, alkyl, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl,
Trifyl, it is alternatively that, RbWith RcFive or hexa-atomic naphthenic base or heterocycle R can be formedaWith RdIt is each independently selected from virtue
Base, heteroaryl, alkyl, alkoxy, naphthenic base, heterocycle, carbonyl, ester group, bridged ring base, loop coil base or simultaneously ring group.
" alkenyl " refer at least composition containing carbon-to-carbon double bond as hereinbefore definition alkyl, preferably comprise 2 to 20
A carbon atom, further preferred 2 to 12 carbon atoms more preferably have 2 to 8 carbon atoms on main chain, and alkenyl can be substitution
Or it is unsubstituted.Non-limiting embodiment includes vinyl, allyl, 1- acrylic, 2- acrylic, 1- cyclobutenyl, 2- fourth
Alkenyl, 3- cyclobutenyl, 1- pentenyl, 2- pentenyl, 3- pentenyl, 4- pentenyl, 1- methyl-1-cyclobutenyl, 2-methyl-1-butene
Alkenyl, 2- methyl -3- cyclobutenyl, 1- hexenyl, 2- hexenyl, 3- hexenyl, 4- hexenyl, 5- hexenyl, 1- methyl-1-pentene
Alkenyl, 2- methyl-1-pentene alkenyl, 1- heptenyl, 2- heptenyl, 3- heptenyl, 4- heptenyl, 1- octenyl, 3- octenyl, 1-
Nonenyl, 3- nonenyl, 1- decene base, 4- decene base, 1,3- butadiene, 1,3- pentadiene, 1,4- pentadiene, 1,4- oneself two
Alkene, 14 carbon trialkenyl of 3- hendecene base, 4- laurylene base and 4,8,12- etc..When substituted, substituent group is selected from for 1 to 5
F, Cl, Br, I, alkyl, naphthenic base, alkoxy, halogenated alkyl, mercaptan, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, virtue
Base, heteroaryl, heterocycle, bridged ring base, loop coil base, and ring group, hydroxy alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-
(CH2)m- C (=O)-Ra、-O-(CH2)m- C (=O)-Ra、-(CH2)m- C (=O)-NRbRc、-(CH2)mS (=O)nRa、-
(CH2)mAlkenyl-Ra、ORdOr-(CH2)mAlkynyl-Ra(wherein 0,1 or 2 m, n), artyl sulfo, thiocarbonyl, silylation
Or-NRbRc, wherein RbWith RcIt is independently selected from including H, hydroxyl, amino, carbonyl, alkyl, alkoxy, naphthenic base, heterocycle, virtue
Base, heteroaryl, sulfonyl, trifyl, it is alternatively that, RbWith RcFive or hexa-atomic naphthenic base or heterocycle can be formed.RaWith
RdBe each independently selected from aryl, heteroaryl, alkyl, alkoxy, naphthenic base, heterocycle, carbonyl, ester group, bridged ring base, loop coil base or
And ring group.
" alkynyl " refer to comprising at least one carbon-carbon triple bond composition as hereinbefore definition alkyl, preferably comprise 2 to
20 carbon atoms, further preferred 2 to 8 carbon atoms, more preferably there is the alkynyl of 2 to 4 carbon atoms on main chain.Alkynyl can be with
It is substituted or unsubstituted.Non-limiting embodiment includes acetenyl, 1- propinyl, 2-propynyl, butynyl, 2- butine
Base, 3- butynyl, 1- methyl -2-propynyl, 4- pentynyl, 3- pentynyl, 1- methyl -2- butynyl, 2- hexin base, 3- hexin
Base, 2- heptynyl, 3- heptynyl, 4- heptynyl, 3- octynyl, 3- n-heptylacetylene base, 4- decynyl, 3- undecyne base and 4- dodecyne
Base etc.;When substituted, substituent group is preferably one or more following groups, independently selected from F, Cl, Br, I, alkyl, cycloalkanes
Base, alkoxy, halogenated alkyl, mercaptan, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, aryl, heteroaryl, heterocycle, bridge
Ring group, loop coil base and ring group, hydroxy alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=O)-Ra、-O-
(CH2)m- C (=O)-Ra、-(CH2)m- C (=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、ORdOr-
(CH2)mAlkynyl-Ra(wherein 0,1 or 2 m, n), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith RcIt is independent
Selected from including H, hydroxyl, amino, carbonyl, alkyl, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl, fluoroform
Sulfonyl, it is alternatively that, RbWith RcFive or hexa-atomic naphthenic base or heterocycle can be formed.RaWith RdIt is each independently selected from aryl, heteroaryl
Base, alkyl, alkoxy, naphthenic base, heterocycle, carbonyl, ester group, bridged ring base, loop coil base or simultaneously ring group.
" amino " refers to-NH2, can be substituted or unsubstituted, when substituted, substituent group be preferably 1 to 3 with
Lower group, independently selected from alkyl, naphthenic base, halogenated alkyl, mercaptan, hydroxyl, sulfydryl, amino, cyano, isocyano group, aryl, miscellaneous
Aryl, heterocycle, bridged ring base, loop coil base and ring group, hydroxy alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=
O)-Ra、-O-(CH2)m- C (=O)-Ra、-(CH2)m- C (=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、
ORdOr-(CH2)mAlkynyl-Ra(wherein 0,1 or 2 m, n), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith
RcBe independently selected from including H, hydroxyl, amino, carbonyl, alkyl, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl,
Trifyl, it is alternatively that, RbWith RcFive or hexa-atomic naphthenic base or heterocycle can be formed.RaWith RdIt is each independently selected from virtue
Base, heteroaryl, alkyl, alkoxy, naphthenic base, heterocycle, carbonyl, ester group, bridged ring base, loop coil base or simultaneously ring group.
" acyl group " or " carbonyl " refers to-C (=O)-RaGroup, wherein RaAs defined above.
" aldehyde " refers to-C (=O)-H.
" halogen " refers to fluorine, chlorine, bromine, iodine.
" hydroxyl " refers to-OH.
" cyano " refers to-C ≡ N.
" isocyano group " refers to-N ≡ C.
" nitro " refers to-NO2。
" carboxylic acid " refers to-C (=O)-OH.
" carboxylate " refers to-C (=O)-O-Rd, RdSelected from alkyl, naphthenic base or heterocycle.
" naphthenic base " refers to substituted or unsubstituted saturated or unsaturated cyclic hydrocarbon radical, can be 3 to 10 yuan of monocycle,
4 to 20 yuan of loop coil and ring or bridged ring.Ring carbon atom includes 3 to 20 carbon atoms, and preferably 3 to 10 carbon atoms are further excellent
3 to 8 carbon atoms are selected, non-limiting embodiment includes cyclopropyl, cyclobutyl, cyclopenta, cyclohexyl, suberyl, cyclooctyl, ring
Acrylic, cyclobutane base, cyclopentenyl, cyclohexenyl group, cycloheptenyl, 1,5- cyclo-octadiene base, 1,4- cyclohexadienyl and ring
Heptantriene base etc..When substituted, substituent group is 1 to 5 selected from F, Cl, Br, I, alkyl, naphthenic base, alkoxy, alkyl halide
Base, mercaptan, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, aryl, heteroaryl, heterocycle, bridged ring base, loop coil base and ring
Base, hydroxy alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=O)-Ra、-O-(CH2)m- C (=O)-Ra、-
(CH2)m- C (=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、ORdOr-(CH2)mAlkynyl-Ra(wherein m, n
For 0,1 or 2), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith RcBe independently selected from including H, hydroxyl, amino,
Carbonyl, alkyl, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl, trifyl, it is alternatively that, RbWith Rc
Five or hexa-atomic naphthenic base or heterocycle can be formed.RaWith RdBe each independently selected from aryl, heteroaryl, alkyl, alkoxy, naphthenic base,
Heterocycle, carbonyl, ester group, bridged ring base, loop coil base or simultaneously ring group.
" heterocycle " refers to substituted or unsubstituted saturation or unsaturation and at least containing 1 to 5 selected from N, O or S
Heteroatomic non-aromatic ring, non-aromatic ring can be 3 to 10 yuan of monocycle, 4 to 20 yuan of loop coil and ring or bridged ring, heterocycle
N, the S selectively replaced in ring can be oxidized to various oxidation state.It is preferred that 3 to 12 circle heterocyclic rings.Non-limiting embodiment includes oxygen
Heterocycle propyl, oxetanylmethoxy, oxocyclopentyl, oxacyclohexyl, oxacyclohexyl, oxa- cyclooctyl, aziridine
Base, azelidinyl, azepine cyclopenta, piperidyl, aziridinyl, 1,3 dioxy cyclopenta, 1,4- dioxy ring penta
Base, 1,3- dioxy cyclopenta, 1,3- dioxocyclohex base, bis- sulphur cyclohexyl of 1,3-, azepine base, morpholinyl, piperazinyl, pyrrole
Mutter base, piperidyl, thio-morpholinyl, dihydropyran, 1,4- Dioxin base,
OrDeng.When substituted, substituent group is 1 to 5 selected from F, Cl, Br, I, alkyl, naphthenic base, alkoxy, alkyl halide
Base, mercaptan, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, aryl, heteroaryl, heterocycle, bridged ring base, loop coil base and ring
Base, hydroxy alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=O)-Ra、-O-(CH2)m- C (=O)-Ra、-
(CH2)m- C (=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、ORdOr-(CH2)mAlkynyl-Ra(wherein m, n
For 0,1 or 2), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith RcBe independently selected from including H, hydroxyl, amino,
Carbonyl, alkyl, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl, trifyl, it is alternatively that, RbWith Rc
Five or hexa-atomic naphthenic base or heterocycle can be formed.RaWith RdBe each independently selected from aryl, heteroaryl, alkyl, alkoxy, naphthenic base,
Heterocycle, carbonyl, ester group, bridged ring base, loop coil base or simultaneously ring group.
" benzyl " refers to-CH2Phenyl, the phenyl be it is substituted or unsubstituted, non-limiting embodiment include-
CH2Phenyl ,-CH2P-methylphenyl etc..
" aryl " refers to substituted or unsubstituted 6 to 14 yuan of cyclic aromatic groups, including mono-cyclic aromatic base and condensed ring virtue
Perfume base.It is preferred that 6 to 14 yuan of aromatic rings, further preferred 6 to 10 yuan of aromatic rings, non-limiting example include phenyl, naphthalene, anthracene
Base and phenanthryl etc..The aryl rings can be condensed on heteroaryl, heterocycle or cycloalkyl ring, wherein being connected to precursor structure
Ring together is aryl rings, and non-limiting embodiment includes:
When substituted, substituent group is 1 to 5 selected from F, Cl, Br, I, alkyl, naphthenic base, alkoxy, halogenated alkyl, sulphur
Alcohol, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, aryl, heteroaryl, heterocycle, bridged ring base, loop coil base and ring group, hydroxyl
Base alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=O)-Ra、-O-(CH2)m- C (=O)-Ra、-(CH2)m-C
(=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、ORdOr-(CH2)mAlkynyl-Ra(wherein m, n 0,1 or
2), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith RcIt is independently selected from including H, hydroxyl, amino, carbonyl, alkane
Base, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl, trifyl, it is alternatively that, RbWith RcIt can be formed
Five or hexa-atomic naphthenic base or heterocycle.RaWith RdIt is each independently selected from aryl, heteroaryl, alkyl, alkoxy, naphthenic base, heterocycle
Base, carbonyl, ester group, bridged ring base, loop coil base and ring group.
" heteroaryl " refers to substituted or unsubstituted 5 to 14 yuan of aromatic rings, and is selected from N, O or S (=O) containing 1 to 5n
Hetero atom or group, preferably 5 to 10 yuan of miscellaneous aromatic rings, further preferred 5 to 6 yuan.The non-limiting embodiment of heteroaryl includes
But be not limited to pyridyl group, furyl, thienyl, pyridyl group, pyranose, N- alkyl pyrrole radicals, pyrimidine radicals, pyrazinyl, pyridazinyl,
Imidazole radicals, piperidyl, oxazolyl, pyrazolyl, oxadiazoles base, thiadiazolyl group, 1,3- dithiane, benzimidazole, piperazine sting base, benzo
Imidazoles, benzo pyridine, pyrrolopyridine etc..The heteroaryl ring can be condensed on aryl, heterocycle or cycloalkyl ring, wherein
The ring to link together with precursor structure is heteroaryl ring, and non-limiting embodiment includes
When substituted, substituent group is 1 to 5 selected from F, Cl, Br, I, alkyl, naphthenic base, alkoxy, halogenated alkyl, sulphur
Alcohol, hydroxyl, nitro, sulfydryl, amino, cyano, isocyano group, aryl, heteroaryl, heterocycle, bridged ring base, loop coil base and ring group, hydroxyl
Base alkyl ,=O, carbonyl, aldehyde, carboxylic acid, carboxylate ,-(CH2)m- C (=O)-Ra、-O-(CH2)m- C (=O)-Ra、-(CH2)m-C
(=O)-NRbRc、-(CH2)mS (=O)nRa、-(CH2)mAlkenyl-Ra、ORdOr-(CH2)mAlkynyl-Ra(wherein m, n 0,1 or
2), artyl sulfo, thiocarbonyl, silylation or-NRbRc, wherein RbWith RcIt is independently selected from including H, hydroxyl, amino, carbonyl, alkane
Base, alkoxy, naphthenic base, heterocycle, aryl, heteroaryl, sulfonyl, trifyl, it is alternatively that, RbWith RcIt can be formed
Five or hexa-atomic naphthenic base or heterocycle.RaWith RdIt is each independently selected from aryl, heteroaryl, alkyl, alkoxy, naphthenic base, heterocycle
Base, carbonyl, ester group, bridged ring base, loop coil base and ring group.
" silylation " refers to that one or more hydrogen atoms in silicomethane are replaced by alkyl and is formed by group, embodiment packet
Include but be not limited to trimethyl silicon substrate, triethyl group silicon substrate, t-Butyldimethylsilyl and tert-butyl diphenyl silicon substrate etc..
" optional " or " optionally " refer to event or environment described later can with but necessarily occur, which includes
The occasion that the event or environment occur or do not occur.Such as: " alkyl optionally replaced by F " refer to alkyl can with but necessarily taken by F
In generation, illustrates to include situation that alkyl is not replaced by the F situation replaced and alkyl by F.
" pharmaceutically acceptable salt " or " its pharmaceutically acceptable salt " refers to keeping the life of free acid or free alkali
Object validity and characteristic, and the free acid by with nontoxic inorganic base or organic base or the free acid by with
Those of nontoxic inorganic acid or organic acid reaction acquisition salt, including alkali metal salt, such as sodium salt, sylvite, lithium salts;Alkaline-earth metal
Salt, such as calcium salt, magnesium salts;Other metal salts, such as molysite, mantoquita, cobalt salt;Organic alkali salt, such as ammonium salt, triethylamine salt, pyridine
Salt, picoline salt, 2,6- lutidines salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, cyclohexylamine salt, ethylenediamine
Salt, guanidine salt, isopropyl amine salt, trismethylamine salt, tripropyl amine salt, triethanolamine salt, diethanolamine salt, ethanolamine salt, diformazan
Ethylethanolamine salt, dicyclohexyl amine salt, coffee alkali salt, procaine salt, choline salt, beet alkali salt, Benethamine Penicillin salt, grape
Osamine salt, N-METHYL-ALPHA-L-GLUCOSAMINE salt, cocoa alkali salt, amino butanetriol salt, purine salt, piperazine salt, alkylbenzyldimethylasaltsum saltsum, piperidinium salt, N- ethyl
Piperidinium salt, tetramethyl amine salt, dibenzyl amine salt and phenylglycine alkyl ester salt etc.;Halogen acid salt, such as hydrofluoride, hydrochloric acid
Salt, hydriodate, hydrobromate etc.;Inorganic acid salt, such as nitrate, sulfate, perchlorate, phosphate;Rudimentary alkyl sulfonic acid
Salt, such as mesylate, fluoroform sulphonate, esilate;Arylsulphonate, such as benzene sulfonate, tosilate;Have
Machine hydrochlorate, such as formate, fumarate, formates, trifluoroacetate, furoate, gluconate, glutamate, glycolic
It is salt, isethionate, lactate, maleate, malate, mandelate, mucus hydrochlorate, embonate, pantothenate, hard
Resin acid salt, succinate, sulfanilate, tartrate, malonate, 2 hydroxy propanoic acid salt, citrate, salicylate, grass
Hydrochlorate, oxyacetate, glucuronate salt, galacturonic hydrochlorate, citrate, lysine salt, arginine salt, L-aminobutanedioic acid
Salt, cinnamate etc..
" pharmaceutical composition " indicate compound or its physiology/pharmaceutically acceptable salt described in one or more texts or
The combination of pro-drug or/and clinically use for treat, prevent diabetes drug or/and SGLT-2 inhibitor or/
With the mixture of DPP-IV inhibitor and other constituents, wherein other components include physiology/pharmaceutically acceptable load
Body and excipient.Clinically using includes biguanides, thiazolidinedione, sulfonylureas, column for treating, preventing the drug of diabetes
How, alpha-glucosidase restrainer, GLP-1 analog or its pharmaceutically acceptable salt, such as melbine, insoral,
Ciglitazone (Ciglitazone), pioglitazone (Pioglitazone), Rosiglitazone (Rosiglitazone), troglitazone
(Troglitazone), Fa Gelie ketone (Farglitazar), Darglitazone (Darglitazoan), Glimepiride
(Glimepiride), orinase (Tolglybutamide), Glibornuride (Glibornuride), glibenclamide
(Glibenclamide), gliquidone (Gliquidone), Glipizide (glipizide), gliclazide
(gliclazipe), Nateglinide (Nateglinide), Repaglinide (Repaglinide), Mitiglinide
(mitiglinide), acarbose (Acarbose), voglibose (Voglibose), Miglitol (Miglitol), Chinese mugwort
Fill in that peptide (Exenatide) or Liraglutide (Liraglutide), SGLT-2 inhibitor such as Dapagliflozin
(Dapagliflozin), canagliflozin (Canagliflozin), En Palie net (Empagliflozin), Yi Palie are net
(Ipragliflozin), Tuo Fulie net (Tofogliflozin), Lu Silie net (Luseogliflozin), Rui Gelie are net
(Remogliflozin), Sergliflozin (Sergliflozin) or support arrange net (Ertugliflozin), DPP-IV inhibitor
Such as BI 1356 (Linagliptin), sitagliptin (Sitagliptin), vildagliptin (Vildagliptin), A Gelie
Spit of fland (Alogliptin), saxagliptin (Saxagliptin), Na Lieting (Denagliptin), carmegliptin
(Carmegliptin), melogliptin (Melogliptin), dutogliptin (Dutogliptin), replace Ge Lieting
(Teneligliptin), gigue column spit of fland (Gemigliptin) or song Ge Lieting (Trelagliptin).The mesh of pharmaceutical composition
Be promote compound on organism body administration.
" carrier " refers to that obvious stimulation will not be generated to organism and will not eliminate the bioactivity of given compound
With the carrier or diluent of characteristic.
" excipient " refers to being added to the inert substance that compound administration is further relied in pharmaceutical composition.It assigns
The example of shape agent include but is not limited to calcium carbonate, calcium phosphate, various sugar and different types of starch, cellulose derivative (including
Microcrystalline cellulose), gelatin, vegetable oil, polyethylene glycols, diluent, granulating agent, lubricant, adhesive, disintegrating agent etc..
" prodrug ", which refers to, to be converted into biologically active chemical combination of the present invention in physiological conditions or by solvolysis
The compound of object.Prodrug of the invention prepared by the phenolic group group modified in the compound, which can routinely
Operation is removed in vivo, and obtains parent compound.It is preceding when pro-drug of the invention is delivered to mammalian subject
Body drug is isolated and is respectively formed free hydroxyl.The example of prodrug includes, but are not limited to the phenolic hydroxyl group of the compounds of this invention
With phosphoric acid at sodium salt derivative.
Certain compounds as described herein can be used as tautomer presence, along with turning for one or more double bonds
It moves, there is different hydrogen tie points.Such as ketone-enol tautomers.Single tautomer and its mixture are included in
The range of the compounds of this invention.Tautomer within the scope of the compounds of this invention includes but is not limited to:
Compound described herein can be containing one or more asymmetric centers, and it is possible thereby to racemate, outer
Racemic mixture, single enantiomter, non-enantiomer mixture and single diastereoisomer exist.
Certain compounds described herein contain double bond, include E and Z geometry structure body unless otherwise indicated.
" X syndrome " refers to the illness, disease and illness of metabolic syndrome.Detailed description is shown in Johannsson
J.Clin.Endocrinol.Metab.,1997,82,727-734。
The amount for the compound that " effective dose " has guided tissue, system or subject physiologic or medicine to translate, this amount is institute
Seek, the one or more of symptoms for being enough to prevent treated illness or illness with subject when including applying occur
Or mitigate it to the amount of compound to a certain degree.
" solvate " refers to the compounds of this invention or its salt, they further include in terms of the chemistry that non-covalent intermolecular forces combine
Amount or non-stoichiometric solvent.It is then hydrate when solvent is water.
“IC50" refer to half-inhibitory concentration, refer to concentration when reaching maximum suppression effect half.
The synthetic method of the compounds of this invention
In order to complete the purpose of the present invention, the compounds of this invention can be prepared by following scheme:
Scheme one:
Intermediate compound I-A and I-B obtains intermediate compound I-C by reductive amination conditioned response, and intermediate compound I-C passes through removing again
Amino protecting group obtains logical formula (I) compound.
Scheme two:
Intermediate compound I-D and intermediate compound I-E obtains intermediate compound I-C by condensation reaction, and intermediate compound I-C is protected by deamination
Base obtains logical formula (I) compound.
The preparation of intermediate compound I-A referenced patent WO2010056708, US2007232676 document, method are described as follows:
Wherein, R1、R1a、R1b、R1c、R1dIt is as hereinbefore defined with W, R2aSelected from C1-8Alkyl or C3-8Naphthenic base, P are amino
Protecting group, for example tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or 9- fluorenylmethoxycarbonyl groups (Fmoc), V are halogen,
It is preferred that chlorine, L is selected from halogen, preferably bromine.
Specific embodiment
Below by way of the beneficial effect of the specific embodiment implementation process that the present invention will be described in detail and generation, it is intended to which help is read
Reader more fully understands essence and feature of the invention, does not limit the scope of the present invention.
The structure of compound is by nuclear magnetic resonance (NMR) and/or mass spectrum (MS) come what is determined.
The measurement of NMR is to use (Bruker ADVANCE III 400) nuclear magnetic resonance spectrometer, and measurement solvent is deuterated dimethyl sulfoxide
(DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), inside it is designated as tetramethylsilane (TMS).
(Agilent 6120B (ESI)) is used in the measurement of MS.
The measurement of HPLC uses Agilent 1260DAD high pressure liquid chromatograph (Zorba x SB-C18100x 4.6mm).
Tlc silica gel plate uses Yantai Huanghai Sea HSGF254 or Qingdao GF254 silica gel plate, and thin-layered chromatography (TLC) makes
The specification that silica gel plate uses is 0.15mm~0.20mm, thin-layer chromatography isolate and purify product use specification be 0.4mm~
0.5mm。
Column chromatography is generally carrier using 200~300 mesh silica gel of Yantai Huanghai Sea silica gel.
Without specified otherwise, methyl tertiary butyl ether(MTBE), hydrazine hydrate, tetrabutylammonium bromide, sodium hydride, triphenyl phosphorus, N, N- bis-
Methylacetamide, glycol dimethyl ether, trifluoroacetic acid purchase are in Chengdu Ke Long chemical reagent factory;Two dimethyl dicarbonate butyl esters,
N, N'- dicarbapentaborane diimidazole, N,N-dimethylformamide dimethylacetal, n-BuLi, N, the purchase of O- dimethyl hydroxylamine hydrochloride
It buys in special (Chengdu) the medical science Co., Ltd of Ace;Cesium carbonate, N- hydroxysuccinimide, two (trimethyl silicon substrate) amino
Sodium, the purchase of diphenyl methylene glycine ethyl ester are in the resistance to Jilin Chemical of peace;Ammonia/methanol purchase is in the limited public affairs of the smooth scientific and technological share of upper Haitai
Department;2- (trimethylsilyl) ethoxymethyl chlorine, the purchase of 2,5- difluoro bromobenzene are in Shanghai De Mo Pharmaceutical Technology Co., Ltd;Isopropyl
Base magnesium chloride/lithium chloride tetrahydrofuran solution purchase is in lark prestige Science and Technology Ltd.;Tetrabutyl ammonium fluoride, three (acetoxyl groups)
Sodium borohydride, propargyl bromide, the purchase of tetrabutyl hexafluorophosphoric acid amine are in this Reagent Company of Adama;Cyclopentadienyl group is bis- (triphenylphosphine)
Ruthenic chloride (II) is bought in ACROS orgainics;Cyclopropyl sulfonyl chloride, borane dimethylsulf iotade purchase are in splendid remote chemistry science and technology
(Shanghai) Co., Ltd.;Benzene sulfonic acid purchase recovers fine chemistry industry research institute in Tianjin;Chlorine { [(1R, 2R)-(-) -2- amino -1,2-
Diphenyl-ethyl] (phenyl-pentafluoride sulphonyl) amino (p-cymene) ruthenium (II) purchase in Strem chemical;Cobalt octacarbonyl purchase
It buys in AlfaAesar reagent;Lithium diisopropylamine is bought in Aladdin reagent.
Nitrogen atmosphere refers to that reaction flask connects the nitrogen balloon of an about 1L volume.Nitrogen atmosphere refers to that reaction flask connects one about
The hydrogen balloon of 2L volume.Hydrogenation usually vacuumizes, and is filled with hydrogen, operates 3 times repeatedly.Without specified otherwise in embodiment,
Solution refers to aqueous solution.Without specified otherwise in embodiment, the temperature of reaction is room temperature.It abridges in embodiment: Bn: benzyl;Et: second
Base;Ac: acetyl group;Me: methyl;Boc: tertbutyloxycarbonyl;Ph: phenyl;COOH: carboxyl;OMe: methoxyl group;OTBS: dimethyl
Tert-butyl silicon ether;SO3H: sulfonic group;Ms: methyl sulphonyl;SEM:2- (trimethyl silicane) ethoxyl methyl.
Intermediate 1
Tert-butyl ((2R, 3S) -2- (2,5- difluorophenyl) -5- carbonyl tetrahydro -2H- pyrans -3- base) carbamate (in
Mesosome 1)
tert-butyl((2R,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-
yl)carbamate
Step 1: ethyl 2- Aminopentyl -4- acetylenic acid ester (1B)
ethyl 2-aminopent-4-ynoate
At room temperature, diphenyl methylene glycine ethyl ester 1A (50g, 0.187mol) is dissolved in methyl tertiary butyl ether(MTBE) (300mL)
In, propargyl benzene sulfonate (44g, 0.224mol), tetrabutylammonium bromide (6.1g, 0.019mol) are added in reaction solution, risen
Temperature is added cesium carbonate (121.8g, 0.374mol) to 50 DEG C, reacts overnight at a temperature of 50 DEG C.Reaction solution is filtered, methyl is used
Tertbutyl ether (40mL × 2) washs filter cake, merges organic phase, and after the solvent of the more than half volumes of concentrated by rotary evaporation, hydrochloric acid solution is added
(3mol/L, 100mL) is stirred 1 hour, stratification at room temperature, and water phase is extracted with methyl tertiary butyl ether(MTBE) (70mL × 2), is collected
Water phase obtains 1B.
Step 2: 2- ((tertbutyloxycarbonyl) amino) -4- alkynes valeric acid (1C)
2-((tert-butoxycarbonyl)amino)pent-4-ynoic acid
Sodium hydroxide (33.7g, 0.842mol) is dissolved in water (100mL), is added dropwise to 1B (26.4g, 0.187mol) dropwise
Reaction solution in, at room temperature stir 2 hours.Two dimethyl dicarbonate butyl esters (45g, 0.206mol) are dissolved in methyl tertiary butyl ether(MTBE)
(125mL), is added dropwise in reaction solution, stirs 4 hours at room temperature.Stratification, water phase are washed with methyl tertiary butyl ether(MTBE) (80mL × 2)
It washs, the water phase hydrochloric acid solution of 3mol/L adjusts pH value to 3, and it is extracted with methyl tertiary butyl ether(MTBE) (100mL × 2), merges organic phase,
Saturated sodium-chloride water solution (30mL × 2) washs, and anhydrous magnesium sulfate is added in organic phase and dries, filters, is spin-dried for, obtains yellow oil
Shape liquid 1C (33g, yield 83%).
MS m/z(ESI):212.0[M-1]。
Step 3: tert-butyl (6- methoxyl group -5- carbonyl hept- 1- alkynes -4- base) carbamate (1D)
tert-butyl(6-methoxy-5-oxohept-1-yn-4-yl)carbamate
1C (33g, 0.155mol) is dissolved in n,N-Dimethylformamide (200mL), controls temperature less than 10 DEG C, by N,
N'- carbonyl dimidazoles (32.58g, 0.201mol) add in reaction solution, react 1 hour at 0 DEG C.By N, O- dimethyl oxyammonia salt
Hydrochlorate (19.6g, 0.186mol) adds in reaction solution, is stirred overnight at room temperature.It is added dropwise water (150mL), stirs 1 hour, use
Ethyl acetate (100mL × 2) extraction, merges organic phase, with saturated sodium bicarbonate solution (60mL × 3), saturated sodium chloride solution
(60mL × 3) wash organic phase, and it is dry that anhydrous magnesium sulfate is added in organic phase.Filtering, filtrate is concentrated, is used column chromatography
(petrol ether/ethyl acetate (v/v)=10:1) obtains white solid 1D (35g, yield 88.2%).
MS m/z(ESI):156.9[M+1]。
Step 4: tert-butyl (the amyl- 4- alkynes -2- base of 1- (2,5- difluorophenyl) -1- carbonyl) carbamate (1E)
tert-butyl(1-(2,5-difluorophenyl)-1-oxopent-4-yn-2-yl)carbamate
Under nitrogen protection, 2,5- difluoro bromobenzene (15.05g, 78mmol) is dissolved in dry toluene (50mL), ice salt bath cooling
To -10 DEG C hereinafter, isopropylmagnesium chloride/lithium chloride tetrahydrofuran solution (66mL, 1.3mol/L) is added dropwise, it is maintained at -10
DEG C or so stirring 1 hour.1D (10g, 39mmol) is dissolved in dry tetrahydrofuran (100mL), is added dropwise to above-mentioned reaction dropwise
In liquid, -10 DEG C are maintained the temperature at hereinafter, finish, is reacted 4 hours at room temperature.- 10 DEG C are cooled the temperature to hereinafter, being added dropwise
Saturated ammonium chloride solution (40mL) stirs 10 minutes, adjusts pH value to 5~6 with the hydrochloric acid solution of 3mol/L, stratification, water
It is mutually extracted with methyl tertiary butyl ether(MTBE) (50mL × 2), merges organic phase, washed with saturated sodium chloride solution (30mL × 2), organic phase
Middle addition anhydrous sodium sulfate dries, filters, and concentration, column chromatography for separation (petrol ether/ethyl acetate (v/v)=50:1-8:1) obtains
To faint yellow solid 1E (10.1g, yield 83.5%).
MS m/z(ESI):210.1[M+1]。
Step 5: tert-butyl (the amyl- 4- alkynes -2- base of (1R, 2S) -1- (2,5- difluorophenyl) -1- hydroxyl) carbamate
(1F)
tert-butyl((1R,2S)-1-(2,5-difluorophenyl)-1-hydroxypent-4-yn-2-yl)
carbamate
1E (16.07g, 52mmol) is dissolved in tetrahydrofuran (100mL), is added triethylene diamine (17.39g, 155mmol)
With [(R, R)-N- (2- amino -1,2- Diphenethyl) pentafluorobenzenesulfonamide] chlorination (p-cymene) ruthenium (II) (i.e. RuCl (p-
Cymene) (R, R)-FSDPEN) (0.37g, 0.52mmol), formic acid (14.27g, 310mmol) is added dropwise, finishes, in 40 DEG C
Reaction is overnight.The tetrahydrofuran and formic acid in reaction solution are rotated, water (60mL), hydrochloric acid (3mol/L, 10mL) is added, uses methyl
Tertbutyl ether (90mL × 3) extraction merges organic phase, and saturated sodium bicarbonate solution (35mL × 2) washs, and nothing is added in organic phase
Water magnesium sulfate dries, filters, and concentration, column chromatography for separation (petrol ether/ethyl acetate (v/v)=60:1-10:1) obtains faint yellow
Jelly 1F (15.37g, yield 95%).
MS m/z(ESI):334.2[M+23]。
Step 6: tert-butyl ((2R, 3S) -2- (2,5- difluorophenyl) -3,4- dihydro -2H- pyrans -3- base) carbamic acid
Ester (1G)
tert-butyl((2R,3S)-2-(2,5-difluorophenyl)-3,4-dihydro-2H-pyran-3-yl)
carbamate
It will be dissolved in n,N-Dimethylformamide (75mL) under 1F (15.37g, 49.4mmol) heating condition, the tetrabutyl be added
Hexafluorophosphoric acid amine (2.49g, 6.42mmol), N- hydroxysuccinimide (2.84g, 24.75mmol), triphenylphosphine (0.86g,
3.26mmol), sodium bicarbonate (2.16g, 25.69mmol), nitrogen are replaced three times, are vacuumized 15 minutes, and cyclopentadienyl group is added
Bis- (triphenylphosphine) ruthenic chloride (II) (i.e. CpRuCl (PPh3)2) (1.79g, 2.47mmol), nitrogen is replaced three times, and is vacuumized
15 minutes, under nitrogen protection, it is warming up to 85 DEG C of reactions overnight.Water (300mL), methyl tertiary butyl ether(MTBE) are added in reaction solution
(200mL), is filtered with silica gel, filtrate stratification, and water phase is extracted with methyl tertiary butyl ether(MTBE) (90mL × 2), merges organic phase, is used
Saturated sodium bicarbonate solution (60mL × 2) washs, and anhydrous sodium sulfate is added in organic phase and dries, filters concentration, column chromatography for separation
(petrol ether/ethyl acetate (v/v)=80:1-30:1) obtains pale yellow powder solid 1G (8.9g, yield 57.9%).
MS m/z(ESI):256.2[M+1]。
Step 7: tert-butyl ((2R, 3S) -2- (2,5- difluorophenyl) -5- hydroxy tetrahydro -2H- pyrans -3- base) amino first
Acid esters (1H)
tert-butyl((2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-
pyran-3-yl)carbamate
1G (8.9g, 28.6mmol) is dissolved in dry methyl tertiary butyl ether(MTBE) (90mL), is added dry toluene (9mL),
Temperature is down to -10 DEG C, and borane dimethylsulf iotade tetrahydrofuran solution (2mol/L, 35.9mL) is added dropwise, reacts 3.5 at 0 DEG C
Hour.It is slowly added to water (4mL), is added dropwise sodium hydroxide solution (1mol/L, 89mL), stirs 15 minutes, was added portionwise
Boratex (13.2g, 85.8mmol), is stirred overnight at room temperature.Stratification, water phase are extracted with methyl tertiary butyl ether(MTBE) (50mL × 2),
Merge organic phase, saturated sodium chloride solution (20mL × 2) washing, organic phase is dried, filtered with anhydrous sodium sulfate, is concentrated, is added
Toluene (50mL) is heated to 90 DEG C of dissolutions, n-hexane (200mL) is added dropwise in reaction solution, white solid is precipitated, filters, just
Hexane (30mL × 2) washs filter cake, and concentration removes solvent, obtains white solid powder 1H (7.9g, yield 84%).
MS m/z(ESI):274.1[M+1]。
Step 8: tert-butyl ((2R, 3S) -2- (2,5- difluorophenyl) -5- carbonyl tetrahydro -2H- pyrans -3- base) amino first
Acid esters (intermediate 1)
tert-butyl((2R,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-
yl)carbamate
1H (11.53g, 35.03mmol) is dissolved in methylene chloride (130mL), is cooled to 0 DEG C, this Martin oxidation will be worn
Agent (Dess-Martin periodinane) (29.72g, 70.06mmol) adds in reaction solution in batches, is warmed to room temperature naturally anti-
It answers 4 hours.It is cooled to 0 DEG C, saturated sodium bicarbonate solution (60mL) is added dropwise in reaction solution, is stirred 20 minutes, filtering, filtrate
Stratification, water phase with methyl tertiary butyl ether(MTBE) (60mL × 3) extract, merge organic phase, with saturated sodium bicarbonate solution (30mL ×
2) it washs, anhydrous sodium sulfate is added in organic phase and dries, filters concentration, column chromatography for separation (petrol ether/ethyl acetate (v/v)=
10:1-4:1), White crystal powder intermediate 1 (10.85g, yield 94.7%) is obtained.
MS m/z(ESI):272.0[M+1];
1H NMR(400MHz,DMSO-d6):δ7.29-7.13(m,4H),4.77-4.75(d,2H),4.22-4.12(d,
2H),4.08-4.02(m,1H),2.75-2.70(m,2H),1.23(s,9H)。
Intermediate 2
Tert-butyl 3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-formic acid
Ester (intermediate 2)
tert-butyl 3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-
c]pyrazole-5(6H)-carboxylate
Step 1: tert-butyl allyl (support -2- alkynes -1- base) carbamate (2B)
tert-butyl allyl(prop-2-yn-1-yl)carbamate
N- tertbutyloxycarbonyl allylamine 2A (20g, 127.39mmoL) is dissolved in n,N-Dimethylformamide (100mL), it will
After sodium hydride (7.6g, 60%, 191.08mmoL) is handled with n-hexane, it is added n,N-Dimethylformamide (400mL), in nitrogen
It under protection, is added drop-wise in reaction solution at 0 DEG C, is stirred 30 minutes at 0 DEG C, be warmed to room temperature down that the reaction was continued 20 minutes.Under ice bath
It is added dropwise to propargyl bromide (30.3g, 245.78mmoL), is kept for 0 DEG C stir 30 minutes.Reaction solution is slowly added to process in trash ice
The sodium hydride of amount is extracted with ethyl acetate (100mL × 3), is merged organic phase and is washed with saturated salt solution (100mL x 3),
Anhydrous sodium sulfate dries, filters, filtrate decompression concentration.Residue silica gel column chromatography separating purification (petrol ether/ethyl acetate
(v/v)=100:1~50:1), obtain yellow liquid 2B (21g, yield 85%).
MS m/z(ESI):140.1[M+1]。
Step 2: tert-butyl 5- carbonyl hexahydro cyclopentano [c] pyrroles -2 (1H)-formic acid esters (2C)
tert-butyl 5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
Compound 2B (39g, 202.2mmoL) is dissolved in glycol dimethyl ether (275mL), cobalt octacarbonyl is added
(83g, 242.7mmoL), water (82.4mL) stirs 30 minutes, is warming up to 84 DEG C of return stirrings 16 hours.Reaction solution is concentrated,
The hydrochloric acid (240mL) that saturated salt solution (500mL), ethyl acetate (250mL) and 1mol/L is added dissolves residual solid.Liquid separation,
Water phase is extracted with ethyl acetate (250mL x 3), is merged organic phase, is washed with saturated salt solution (250mL × 2), anhydrous slufuric acid
Sodium dries, filters, and pressurization concentration, silica gel column chromatography separating purification (petrol ether/ethyl acetate (v/v)=3:1~2:1) obtains
Faint yellow solid 2C (27.6g, yield 61.3%).
MS m/z(ESI):170.1[M+1];
1H NMR(400MHz,CDCl3):δ3.68-3.64(m,2H),3.24-3.21(d,2H),2.97-2.88(m,2H),
2.52-2.45(dd,2H),2.20-2.14(dd,2H),1.46(s,9H)。
Step 3: (E)-tert-butyl 4- ((dimethylamino) methene) -5- carbonyl hexahydro cyclopentano [c] pyrroles -2
(1H)-formic acid esters (2D)
(E)-tert-butyl 4-((dimethylamino)methylene)-5-oxohexahydrocyclopenta
[c]pyrrole-2(1H)-carboxylate
2C (20g, 88.9mmoL) is dissolved in N,N-dimethylformamide dimethylacetal (13.7g, 115.6mmoL) heating
It is stirred at reflux 4 hours.Reaction solution is concentrated, silica gel column chromatography separating purification (petrol ether/ethyl acetate (v/v)=2:1~1:
4) brown oil 2D (15.8g, yield 63%), is obtained.
MS m/z(ESI):281.2[M+1]。
Step 4: tert-butyl 7a- hydroxyl -3b, 4,6,6a, 7,7a- hexahydro -1H- pyrrolo- [3', 4':3,4] cyclopentano
[1,2-c] pyrazoles -5 (2H)-formic acid esters (2E)
tert-butyl 7a-hydroxy-3b,4,6,6a,7,7a-hexahydro-1H-pyrrolo[3',4':3,4]
cyclopenta[1,2-c]pyrazole-5(2H)-carboxylate
2D (15.8g, 56.4mmoL) is dissolved in toluene (90mL), is added hydrazine hydrate (4.2g, 67.7mmoL, 80%),
It is stirred 16 hours at 45 DEG C.Reaction solution is cooled to room temperature, is filtered, filter cake is eluted with ethyl acetate, filter cake is dried, obtained
White solid 2E (13.6g, yield 90%)
Step 5: tert-butyl 3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5
(6H)-formic acid esters (intermediate 2)
tert-butyl3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]
pyrazole-5(6H)-carb-oxylate
2E (13.6g, 50.9mmoL) is dissolved in methylene chloride (90mL), is cooled to 0 DEG C, p-methyl benzenesulfonic acid hydration is added
Object (0.97g, 5.09mmoL) stirs 30 minutes.Into reaction solution be added saturated sodium bicarbonate solution adjust reacting liquid pH value 7~
8, liquid separation.Water phase is extracted with methylene chloride (500mL × 3), merges organic phase, and washed with saturated salt solution (500mL x 2),
Anhydrous sodium sulfate dries, filters, concentration, silica gel column chromatography separating purification (petrol ether/ethyl acetate (v/v)=1:1~1:2),
Obtain white solid intermediate 2 (10g, yield 78.8%).
1H NMR(400MHz,CD3OD):δ7.33(S,1H),3.76-3.71(m,1H),3.64-3.63(D,2H),3.43
(m,2H),2.95-2.89(m,2H),2.57-2.53(d,1H),1.42(s,9H)。
Intermediate 2 splits to obtain two single configuration compounds, Chiral HPLC color by chiral high performance liquid chromatography
Compose separation condition:
Chiral column: CHIRALPAK AY-H;Chiral column specification: 0.46cm I.D. × 15cm L;Sample volume: 2 μ L;Flowing
Phase: n-hexane/isopropanol (v/v)=90/10;Flow velocity: 1.0mL/min;Detection wavelength: UV 214nm;Temperature: 35 DEG C;
Peak 1:t=3.685min is intermediate 2-1;
Peak 2:t=4.627min is intermediate 2-2;
Intermediate 3
Tert-butyl 3- (trifluoromethyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrrole
Azoles -5 (6H)-formic acid esters (intermediate 3)
tert-butyl 3-(trifluoromethyl)-3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':
3,4]cyclopenta[1,2-c]pyrazole-5(6H)-carboxylate
Step 1: tert-butyl 5- carbonyl -4- (2,2,2- trifluoroacetyl group) hexahydro cyclopentano [c] pyrroles -2 (1H)-formic acid
Ester (3A)
tert-butyl 5-oxo-4-(2,2,2-trifluoroacetyl)hexahydrocyclopenta[c]
pyrrole-2(1H)-carboxylate
At room temperature, 2C (1.13g, 5.0mmol) is dissolved in tetrahydrofuran (15mL), is cooled to -70 DEG C.Diisopropyl is added
Base amido lithium (2.5mL, 2mol/L) reacts 0.5 hour in -70 DEG C.Trifluoroacetic Acid Ethyl Ester (0.71g, 5.0mmol) is added to
In reaction solution, it is warmed to room temperature reaction 4 hours naturally.Reaction system is cooled to -10 DEG C, ammonium chloride (15mL) is added dropwise and arrives reaction solution
In.It is extracted with methyl tertiary butyl ether(MTBE) (40mL × 3), merges organic phase, washed with saturated common salt aqueous solution (30mL × 1).It is anhydrous
Magnesium sulfate dries, filters, and filtrate decompression is concentrated.Residue silica gel column chromatography separating purification (ethyl acetate/petroleum ether (v/
V)=3:1-1:1), obtain brown liquid 3A (1.36g, yield 84%).
MS m/z(ESI):322.1[M+1]。
Second step, step 3:
Tert-butyl 3- (trifluoromethyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrrole
Azoles -5 (6H)-formic acid esters (intermediate 3)
tert-butyl 3-(trifluoromethyl)-3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':
3,4]cyclopenta[1,2-c]pyrazole-5(6H)-carboxylate
At room temperature, 3A (1.36g, 4.23mmol) is dissolved in toluene (20mL), addition hydrazine hydrate (0.26g,
5.08mmol), it reacts 2 hours for 40 DEG C.Water (30mL) is added into reaction system, is extracted, is associated with methylene chloride (50mL)
Machine phase, anhydrous magnesium sulfate dry, filter, and filtrate decompression is concentrated to get 3B.Compound 3B is dissolved in methylene chloride (30mL),
It is cooled to 0 DEG C, anhydrous methanol (10mL) solution of p-methyl benzenesulfonic acid (0.42g, 2.18mmol) is added drop-wise in reaction solution, in 0
DEG C reaction 1 hour.Sodium bicarbonate solution is added dropwise and adjusts reaction solution pH to 8, is extracted with methylene chloride (20mL × 4).Merge organic
Phase is washed with saturated common salt aqueous solution (20mL × 1).Anhydrous magnesium sulfate dries, filters, and filtrate decompression is concentrated.Residue is used
Silica gel column chromatography (ethyl acetate/petroleum ether (v/v)=5:1-1:1) purifying, obtains white solid intermediate 3 (0.44g, yield
32.8%).
MS m/z(ESI):318.3[M+1]。
Embodiment 1
2- (5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -3b, 4,5,6,
6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -2- base) ethyl alcohol (compound 1-1)
2-(5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-
yl)-3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-2-
yl)ethanol
2- (5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -3b, 4,5,6,
6a, 7- hexahydro -1H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazol-1-yl) ethyl alcohol (compound 1-2)
2-(5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-
yl)-3b,4,5,6,6a,7-hexahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-1-
yl)ethanol
Step 1: tert-butyl 2- (2- ethyoxyl -2- carbonylethyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':
3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-formic acid esters (1a-1)
tert-butyl 2-(2-ethoxy-2-oxoethyl)-3b,4,6a,7-tetrahydro-2H-pyrrolo
[3',4':3,4]cyclopenta
[1,2-c]pyrazole-5(6H)-carboxylate
Tert-butyl 1- (2- ethyoxyl -2- carbonylethyl) -3b, 4,6a, 7- tetrahydro-1 H-pyrrolo simultaneously [3', 4':3,4] ring penta
And [1,2-c] pyrazoles -5 (6H)-formic acid esters (1a-2)
tert-butyl 1-(2-ethoxy-2-oxoethyl)-3b,4,6a,7-tetrahydro-1H-pyrrolo
[3',4':3,4]cyclopenta
[1,2-c]pyrazole-5(6H)-carboxylate
Intermediate 2 (2.0g, 8.0mmoL) is dissolved in n,N-Dimethylformamide (20mL), cools to 0 DEG C, hydrogen is added
Change sodium (385mg, 60%, 9.6mmoL), is warmed to room temperature lower stirring 1 hour.0 DEG C is cooled to again, is added dropwise to bromoacetate
(1.6g, 9.6mmoL) is warmed to room temperature stirring 16 hours naturally.Reaction solution is poured into trash ice, is stirred, and suitable chlorine is added
Change sodium, extracted with ethyl acetate (80mL × 3), merge organic phase, and washed with saturated salt solution (50mL x 3), organic phase is used
Anhydrous sodium sulfate dries, filters, and is concentrated under reduced pressure, with silica gel column chromatography separating purification (petrol ether/ethyl acetate (v/v)=2:1),
Obtain the mixture (2g, yield 74%) of colorless oil 1a-1 and 1a-2.
MS m/z(ESI):336.2[M+1]。
Step 2: tert-butyl 2- (2- hydroxyethyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano
[1,2-c] pyrazoles -5 (6H)-formic acid esters (1b-1)
tert-butyl 2-(2-hydroxyethyl)-3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':
3,4]cyclopenta
[1,2-c]pyrazole-5(6H)-carboxylate
Tert-butyl 1- (2- hydroxyethyl) -3b, 4,6a, 7- tetrahydro-1 H-pyrrolo simultaneously [3', 4':3,4] cyclopentano [1,2-c]
Pyrazoles -5 (6H)-formic acid esters (1b-2)
tert-butyl 1-(2-hydroxyethyl)-3b,4,6a,7-tetrahydro-1H-pyrrolo[3',4':
3,4]cyclopenta
[1,2-c]pyrazole-5(6H)-carboxylate
The mixture (830mg, 2.478mmoL) of 1a-1 and 1a-2 is dissolved in methanol (15mL), boron hydrogen is added with stirring
Change sodium (113mg, 2.973mmoL), stirs 4 hours at room temperature.Water (0.5mL) is added into reaction solution, reaction solution is concentrated, is added
Enter saturated salt solution (50mL), extracted with methylene chloride (30mL x 5), merges organic phase, with saturated salt solution (30mL × 1)
Washing, anhydrous sodium sulfate dry, filter, and are concentrated, obtain mixture (710mg, the yield of light yellow oil 1b-1 and 1b-2
97%).
MS m/z(ESI):294.2[M+1]。
Step 3: 2- (3b, 4,5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -2-
Base) ethyl alcohol benzene sulfonate (1c-1)
2-(3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]
pyrazol-2-yl)ethanol benzenesulfonate
2- (3b, 4,5,6,6a, 7- hexahydro -1H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazol-1-yl) ethyl alcohol
Benzene sulfonate (1c-2)
2-(3b,4,5,6,6a,7-hexahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]
pyrazol-1-yl)ethanol benzenesulfonate
By the mixture (580mg, 1.979mmoL) of 1b-1 and 1b-2, benzenesulfonic acid hydrate (476.5mg, 2.573mmoL)
It is dissolved in methanol (10mL), after heating 60 DEG C of stirrings 4 hours and is stirred overnight at room temperature.Reaction solution is concentrated, ethyl acetate is used
(10mL) stirring, is filtered, dry, obtains the mixture (700mg, yield 100%) of colorless oil 1c-1 and 1c-2.
MS m/z(ESI):194.2[M+1]。
Step 4: tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (2- hydroxyethyl) -3b, 4,6a,
7- tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) amino
Formic acid esters (1d-1)
tert-butyl
((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(2-hydroxyethyl)-3b,4,6a,7-
tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)tetrahydro-
2H-pyran-3-yl)carbamate
Tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (1- (2- ethoxy) -3b, 4,6a, 7- tetrahydro -1H-
Pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) carbamate (1d-
2)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(1-(2-hydroxyethyl)-
3b,4,6a,7-tetrahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)
tetrahydro-2H-pyran-3-yl)carbamate
The mixture (1.2g, 3.522mmol) of 1c-1 and 1c-2 is added in there-necked flask, is protected after nitrogen displacement and in nitrogen
Shield is lower to be added n,N-dimethylacetamide (7mL), stirs 1 hour at room temperature.Three (acetoxyl group) sodium borohydrides are added under ice bath
(437.2mg, 1.994mmoL) is stirred at room temperature 16 hours.Concentrated ammonia liquor (20mL) is added into reaction solution under stirring, is stirred at room temperature 1
Hour, filtering, filter cake is washed with clear water (2mL × 5), is dissolved with methylene chloride and methanol mixed solvent (V/V=20:1), anhydrous
Sodium sulphate dries, filters, and is concentrated to get the mixture (250mg, yield 32.5%) of white solid object 1d-1 and 1d-2.
Step 5: 2- (5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -3b,
4,5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -2- base) ethyl alcohol (compound 1-1)
2-(5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-
yl)-3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-2-
yl)ethanol
2- (5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -3b, 4,5,6,
6a, 7- hexahydro -1H- pyrazoles [3', 4':3,4] cyclopentano [1,2-c] pyrazol-1-yl) ethyl alcohol (compound 1-2)
2-(5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-
yl)-3b,4,5,6,6a,7-hexahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-1-
yl)ethanol
The mixture (230mg, 0.456mmoL) of 1d-1 and 1d-2 is added in methylene chloride (1mL), is added three under ice bath
Fluoroacetic acid (1mL) stirs 2 hours.Saturated sodium bicarbonate solution tune reaction solution is added into reaction solution to be in neutrality, saturation food is added
Salt water (20mL) is extracted with methylene chloride (20mL × 3), merges organic phase, saturated salt solution (50mL × 2) washing, anhydrous sulphur
Sour sodium dries, filters, and concentration, residue isolates and purifies (methylene chloride/methanol (v/v)=20:1) with thin-layered chromatography, obtains white
Color solid chemical compound 1-1 (62mg, yield 33%) and compound 1-2 (48mg, yield 26%).
Compound 1-1:Ms m/z (ESI): 405.3 [M+1];
1H NMR(400MHz,CD3OD):δ7.27(s,1H),7.18-7.08(m,3H),4.25-4.23(d,1H),4.20-
4.16(m,1H),4.15-4.12(m,2H),3.85-3.82(m,2H),3.61-3.56(m,2H),3.49-3.47(m,1H),
3.13-2.86(m,4H),2.63-2.48(m,4H),2.40-2.37(d,1H),1.46-1.41(m,1H)。
Compound 1-2:
1H NMR(400MHz,CD3OD):δ7.20-7.04(m,4H),4.24-4.22(d,1H),4.20-4.12(m,1H),
4.07-4.05(m,2H),3.88-3.79(m,2H),3.55(s,2H),3.48-3.31(m,1H),3.19-2.84(m,4H),
2.74-2.45(m,4H),2.40-2.37(d,1H),1.49-1.37(m,1H)。
Embodiment 2
(2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':3,4] ring
Penta simultaneously [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- amino (compound 2)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(3b,4,6a,7-tetrahydro-2H-pyrrolo
[3',4':3,4]cyclopent a[1,2-c]pyrazol-5(6H)-yl)tetrahydro-2H-pyran-3-amine
Step 1: (3b, 4,5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles benzene sulphur
Hydrochlorate (2a)
3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]
pyrazole benzenesulfonate
At room temperature, intermediate 2 (0.250g, 1.00mmol), benzene sulfonic acid (0.250g, 1.50mmol) are dissolved in methanol
In (6mL), 68 DEG C are reacted 12 hours.Reaction solution is concentrated under reduced pressure, white solid 2a (0.362g, yield 100%) is obtained.
MS m/z(ESI):150.3[M+1]。
Step 2: tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (3b, 4,6a, 7- tetrahydro -2H- pyrrolo-
[3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) carbamate (2b)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(3b,4,6a,7-tetrahydro-
2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)tetrahydro-2H-pyran-3-
yl)carbamate
At room temperature, 2a (0.350g, 1.14mmol) is dissolved in n,N-dimethylacetamide (4mL), intermediate 1 is added
(0.338g, 1.04mmol) is stirred 1 hour at 0 DEG C.Three (acetoxyl group) sodium borohydrides (0.285g, 1.34mmol) are added
Into reaction solution, it is warmed to room temperature reaction 16 hours naturally.Reaction solution is cooled to 0 DEG C, sequentially adds water, ammonium hydroxide adjusting pH to 8,
White solid is precipitated.Reaction solution is filtered, filter cake is successively washed with water (5mL × 3), petroleum ether (10mL × 1).It drains, will filter
Biscuit is dry, obtains white solid 2b (0.230g, yield 48.4%).
MS m/z(ESI):461.3[M+1]。
Step 3: (2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':
3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- amino (compound 2)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(3b,4,6a,7-tetrahydro-2H-pyrrolo
[3',4':3,4]cyclopent a[1,2-c]pyrazol-5(6H)-yl)tetrahydro-2H-pyran-3-amine
At room temperature, 2b (0.220g, 0.480mmol) is dissolved in methylene chloride (4mL), is cooled to 0 DEG C, trifluoro second is added
Sour (2mL) reacts 2 hours in 0 DEG C.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution is added dropwise and adjusts pH to 8, uses methylene chloride
(30mL × 3) extraction.Merge organic phase, is washed with saturated common salt aqueous solution (50mL × 1).Anhydrous magnesium sulfate dries, filters, will
Filtrate decompression concentration, prepares plate with thin layer and isolates and purifies (methylene chloride/methanol (v/v)=10:1), obtain shallow white solid chemical combination
Object 2 (0.160g, yield 92.9%).
MS m/z(ESI):361.3[M+1];
1H NMR(400MHz,CD3OD):δ7.27(s,1H),7.04-7.19(m,3H),4.12-4.23(m,2H),3.57-
3.59(m,1H),3.48(s,1H),3.34-3.36(d,1H),3.12(s,1H),2.95-3.02(m,2H),2.79-2.84(m,
1H),2.47-2.57(m,4H),2.36-2.39(d,1H),1.36-1.47(m,1H)。
The 2 optical isomers, that is, compound 3-1 and compound 3-2 of 3 compound 2 of embodiment
Using intermediate 2-1 as raw material, compound 3-1 is obtained referring to the synthetic method of embodiment 2;
MS m/z(ESI):361.3[M+1];
1H NMR(400MHz,CDCl3):δ7.21(s,1H),δ7.14-6.99(m,3H),4.18-4.16(d,1H),
4.14-4.09(m,1H),3.52-3.50(m,1H),3.43-3.29(d,1H),2.97-2.91(m,3H),2.78-2.53(m,
1H),2.44-2.31(m,5H),1.40-1.13(m,4H)。
Using intermediate 2-2 as raw material, compound 3-2 is obtained referring to the synthetic method of embodiment 2;
MS m/z(ESI):361.3[M+1];
1H NMR(400MHz,CDCl3):δ7.17(s,1H),7.10-6.95(m,3H),4.14-4.12(d,1H),4.10-
4.02(m,1H),3.52-3.43(m,1H),3.43(m,1H),3.43-3.29(d,1H),2.97-2.91(m,2H),2.78-
2.53(m,1H),2.71-2.36(m,5H),1.40-1.13(m,4H)。
Embodiment 4
Tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (methyl sulphonyl) -3b, 4,6a, 7- tetrahydro -
2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) carbamate
(compound 4-1)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-
3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)
tetrahydro-2H-pyran-3-yl)carbamate
Tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (1- (methyl sulphonyl) -3b, 4,6a, 7- tetrahydro -
1H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) carbamate
(compound 4-2)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(1-(methylsulfonyl)-
3b,4,6a,7-tetrahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)
tetrahydro-2H-pyran-3-yl)carbamate
Step 1: tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (methyl sulphonyl) -3b, 4,6a,
7- tetrahydro -2H- pyrroles
And [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) carbamate
(4a-1)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-
3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)
tetrahydro-2H-pyran-3-yl)carbamate
Tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (1- (methyl sulphonyl) -3b, 4,6a, 7- tetrahydro -
1H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) carbamate
(4a-2)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(1-(methylsulfonyl)-
3b,4,6a,7-tetrahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)
tetrahydro-2H-pyran-3-yl)carbamate
2b (0.240g, 0.680mmol) is dissolved in n,N-Dimethylformamide (20mL), cools to 0 under nitrogen protection
DEG C, sodium hydride (0.040g, 1.12mmol) is added and stirs 30 minutes, methylsufonyl chloride (0.090g, 1.08mmol) slowly is added dropwise,
It is stirred to react in 0 DEG C 2 hours.Reaction solution is down to 0 DEG C, is added water (100mL), is extracted with methylene chloride (60mL × 3), is merged
Organic phase, saturated common salt aqueous solution (30mL × 1) washing, anhydrous sodium sulfate are dried, filtered, are concentrated, and it is pure that thin layer prepares plate separation
Change (methylene chloride/methanol (v/v)=10:1), obtains the mixture (0.116g, yield 31.7%) of white solid 4a-1 and 4a-2
MS m/z(ESI):538.8[M+1]。
Step 2: tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (methyl sulphonyl) -3b, 4,6a,
7- tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) amino
Formic acid esters (compound 4-1)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-
3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)
tetrahydro-2H-pyran-3-yl)carbamate
(2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (1- (methyl sulphonyl) -3b, 4,6a, 7- tetrahydro-1 H-pyrrolo
And [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- amino (compound 4-2)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(1-(methylsulfonyl)-3b,4,6a,7-
tetrahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)tetrahydro-
2H-pyran-3-amine
The mixture (0.10g, 0.19mmol) of 4a-1 and 4a-2 is added in methylene chloride (2mL), is added three under ice bath
Fluoroacetic acid (1mL) stirs 2 hours.With saturated sodium bicarbonate solution tune reacting liquid pH value to 8, extracted with methylene chloride (20mL × 3)
It takes, merges organic phase, saturated salt solution (50mL × 2) washing, anhydrous sodium sulfate is dried, filtered, is concentrated, and thin layer prepares plate separation
Purify (methylene chloride/methanol (v/v)=10:1), obtain compound as white solid 4-1 and compound 4-2 mixture (0.040g,
Yield 45.6%).
MS m/z(ESI):438.8[M+1];
Compound 4-1 is made of the two kinds of compounds for being relatively diastereoisomer for having the following structure formula, by it
One of number be compound 4-1a, another number is compound 4-1b;
Compound 4-2 is made of the two kinds of compounds for being relatively diastereoisomer for having the following structure formula, will be with
The identical compound number of all chiral centre configurations of compound 4-1a is compound 4-2a, another number is compound 4-
2b;
Using intermediate 2-1 as raw material, the synthetic method of reference implementation example 2 and embodiment 4 be prepared compound 4-1a and
The mixture of compound 4-2a.
The mixture of compound 4-1a and compound 4-2a:1H NMR(400MHz,CDCl3):δ7.79(s,1H),7.17-
7.04(m,3H),4.25-4.23(d,1H),4.19-7.15(m,1H),3.63-3.48(m,2H),2.92-2.32(m,8H),
1.46-1.33(q,2H),1.28(s,3H),0.91-0.87(t,1H)。
Embodiment 5
(2R, 3S, 5R) -5- (2- (Cyclopropylsulfonyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':3,4] ring
Penta simultaneously [1,2-c] pyrazoles -5 (6H)-yl) -2- (2,5- difluoromethyl) tetrahydro -2H- pyrans -3- amino (compound 5-1)
(2R,3S,5R)-5-(2-(cyclopropylsulfonyl)-3b,4,6a,7-tetrahydro-2H-pyrrolo
[3',4':3,4]cyclopen ta[1,2-c]pyrazol-5(6H)-yl)-2-(2,5-difluorophenyl)
tetrahydro-2H-pyran-3-amine
(2R, 3S, 5R) -5- (1- (Cyclopropylsulfonyl) -3b, 4,6a, 7- tetrahydro-1 H-pyrrolo simultaneously [3', 4':3,4] ring
Penta simultaneously [1,2-c] pyrazoles -5 (6H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- amino (compound 5-2)
(2R,3S,5R)-5-(1-(cyclopropylsulfonyl)-3b,4,6a,7-tetrahydro-1H-pyrrolo
[3',4':3,4]cyclopen ta[1,2-c]pyrazol-5(6H)-yl)-2-(2,5-difluorophenyl)
tetrahydro-2H-pyran-3-amine
Step 1: tert-butyl ((2R, 3S, 5R) -5- (2- (Cyclopropylsulfonyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo-
[3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) amino
Formic acid esters (5a-1)
tert-butyl((2R,3S,5R)-5-(2-(cyclopropylsulfonyl)-3b,4,6a,7-
tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)-2-(2,5-
difluorophenyl)tetrahydro-2H-pyran-3-yl)carbamate
Tert-butyl ((2R, 3S, 5R) -5- (1- (Cyclopropylsulfonyl) -3b, 4,6a, 7- tetrahydro-1 H-pyrrolo simultaneously [3', 4':
3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) carbamate
(5a-2)
tert-butyl((2R,3S,5R)-5-(1-(cyclopropylsulfonyl)-3b,4,6a,7-
tetrahydro-1H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)-2-(2,5-
difluorophenyl)tetrahydro-2H-pyran-3-yl)carbamate
At room temperature, 2b (0.200g, 0.430mmol) is dissolved in tetrahydrofuran (20mL), is cooled to 0 DEG C, three second are added
Amine (0.06g, 0.60mmol) reacts 30 minutes.Cyclopropyl sulfonyl chloride (0.080g, 0.560mmol) slowly is added dropwise, it is anti-at 0 DEG C
It answers 2 hours.Reaction solution is down to 0 DEG C, is added water (30mL), is extracted with methylene chloride (30mL × 3), organic phase, saturation are merged
Common salt aqueous solution (30mL × 1) washing, anhydrous sodium sulfate dry, filter, filtrate decompression are concentrated, and residue prepares plate with thin layer
Isolate and purify (methylene chloride/methanol (v/v)=10:1), obtain mixture white solid 5a-1 and 5a-2 mixture (0.090g,
Yield 37.2%).
MS m/z(ESI):564.8[M+1]。
Step 2: (2R, 3S, 5R) -5- (2- (Cyclopropylsulfonyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3', 4':
3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- amino (compound 5-
1)
(2R,3S,5R)-5-(2-(cyclopropylsulfonyl)-3b,4,6a,7-tetrahydro-2H-pyrrolo
[3',4':3,4]cyclopen ta[1,2-c]pyrazol-5(6H)-yl)-2-(2,5-difluorophenyl)
tetrahydro-2H-pyran-3-amine
(2R, 3S, 5R) -5- (1- (Cyclopropylsulfonyl) -3b, 4,6a, 7- tetrahydro-1 H-pyrrolo simultaneously [3', 4':3,4] ring
Penta simultaneously [1,2-c] pyrazoles -5 (6H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- amino (compound 5-2)
(2R,3S,5R)-5-(1-(cyclopropylsulfonyl)-3b,4,6a,7-tetrahydro-1H-pyrrolo
[3',4':3,4]cyclopen ta[1,2-c]pyrazol-5(6H)-yl)-2-(2,5-difluorophenyl)
tetrahydro-2H-pyran-3-amine
At room temperature, the mixture (0.110g, 0.200mmol) of 5a-1 and 5a-2 is dissolved in methylene chloride (3mL), is cooled down
It to 0 DEG C, is added trifluoroacetic acid (1.5mL), is reacted 2 hours in 0 DEG C.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution tune is added dropwise
Reaction solution pH to 8 is saved, is extracted with methylene chloride (30mL × 3).Merge organic phase, is washed with saturated common salt aqueous solution (50mL × 1)
It washs, anhydrous magnesium sulfate dries, filters, and filtrate decompression is concentrated.Residue prepares plate with thin layer and isolates and purifies (methylene chloride/first
Alcohol (v/v)=10:1), obtain the mixture (0.050g, yield 57.8%) of compound as white solid 5-1 and compound 5-2.
MS m/z(ESI):464.9[M+1];
Compound 5-1 is made of the two kinds of compounds for being relatively diastereoisomer for having the following structure formula, by it
One of number be compound 5-1a, another number is compound 5-1b;
Compound 5-2 is made of the two kinds of compounds for being relatively diastereoisomer for having the following structure formula, will be with
The identical compound number of all chiral centre configurations of compound 5-1a is compound 5-2a, another number is compound 5-
2b;
Using intermediate 2-1 as raw material, the synthetic method of reference implementation example 2 and embodiment 5 be prepared compound 5-1a and
The mixture of compound 5-2a.
The mixture of compound 5-1a and compound 5-2a:1H NMR(400MHz,CDCl3):δ7.78-7.77(s,1H),
7.55(s,1H),7.19-7.04(m,6H),4.24-4.22(d,2H),4.19-4.15(m,2H),3.64-3.58(m,3H),
3.51-3.46(m,1H),3.36-3.33(m,2H),3.24-3.17(m,1H),3.12-3.03(m,1H),2.97-2.80(m,
8H),2.78-2.77(m,1H),2.75-2.71(m,2H),2.67-2.63(m,1H),2.61-2.57(m,2H),2.53-2.48
(m,2H),2.39-2.34(m,2H),2.45-1.28(m,8H),1.24-1.11(m,4H),0.90-0.84(m,2H)。
Embodiment 6
(2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (3- (trifluoromethyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo-
[3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- amino (compound 6)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(3-(trifluoromethyl)-3b,4,6a,7-
tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)tetrahydro-
2H-pyran-3-amine
Step 1: 3- (trifluoromethyl) -3b, 4,5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,
2-c] pyrazoles benzene sulfonate (6a)
3-(trifluoromethyl)-3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]
cyclopenta[1,2-c]pyrazo le benzenesulfonate
At room temperature, intermediate 3 (0.420g, 1.32mmol) and benzene sulfonic acid (0.368g, 2.00mmol) are dissolved in methanol
In (14mL), 68 DEG C are reacted 12 hours.Reaction solution is concentrated under reduced pressure, yellow solid 6a (0.460g, yield 92.7%) is obtained.
MS m/z(ESI):218.1[M+1];
Step 2: tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (3- (trifluoromethyl) -3b, 4,6a, 7-
Tetrahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- base) amino first
Acid esters (6b)
tert-butyl((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(3-(trifluoromethyl)-
3b,4,6a,7-tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)
tetrahydro-2H-pyran-3-yl)carbamate
At room temperature, 6a (0.327g, 1.10mmol) is dissolved in n,N-dimethylacetamide (4mL), intermediate 1 is added
(0.356g, 1.10mmol), 0 DEG C is stirred 1 hour.Three (acetoxyl group) sodium borohydrides (0.303g, 1.43mmol) are added to
In reaction solution, it is warmed to room temperature reaction 16 hours naturally.Reaction solution is cooled to 0 DEG C, water is sequentially added and ammonium hydroxide adjusts pH to 8,
White solid is precipitated.Filtering, filter cake are successively washed with water (5mL × 3) and petroleum ether (10mL × 1).It drains, by filtration cakes torrefaction,
It obtains white solid 6b (0.367g, yield 63.7%).
MS m/z(ESI):529.1[M+H+];
Step 3: (2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (3- (trifluoromethyl) -3b, 4,6a, 7- tetrahydro -2H-
Pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) tetrahydro -2H- pyrans -3- amino (compound 6)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(3-(trifluoromethyl)-3b,4,6a,7-
tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazol-5(6H)-yl)tetrahydro-
2H-pyran-3-amine
At room temperature, 6b (0.357g, 0.680mmol) is dissolved in methylene chloride (4mL), is cooled to 0 DEG C, trifluoro second is added
Sour (2mL) reacts 2 hours in 0 DEG C.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution is added dropwise and adjusts pH to 8 in reaction solution.With
Methylene chloride (30mL × 3) extraction merges organic phase, saturated common salt aqueous solution (50mL × 1) washing.Anhydrous magnesium sulfate is dry,
Filtering, filtrate decompression is concentrated.Residue prepares plate with thin layer and isolates and purifies (methylene chloride/methanol (v/v)=10:1), obtains shallowly
Yellow solid compound 6 (0.350g, yield 70.7%).
MS m/z(ESI):428.1[M+1];
1H NMR(400MHz,CDCl3):δ7.12-6.94(m,3H),4.11-4.13(d,1H),4.08-4.05(m,1H),
3.52-3.48(m,2H),3.27-3.24(m,1H),3.01-2.71(m,4H),2.66-2.47(m,3H),2.43-2.27(m,
2H),1.38-1.24(m,2H)。
Embodiment 7
Methyl 5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -3b, 4,5,6,
6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -3- formic acid esters (compound 7)
methyl 5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-
pyran-3-yl)-3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]
pyrazole-3-carboxylate
Step 1: tert-butyl 2- ((2- (trimethyl silicon substrate) ethyoxyl) methyl) -3b, 4,6a, 7- tetrahydro -2H- pyrrolo-
[3', 4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-formic acid esters (7a)
tert-butyl 2-((2-(trimethylsilyl)ethoxy)methyl)-3b,4,6a,7-tetrahydro-
2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazole-5(6H)-carboxylate
At room temperature, intermediate 2 (1.0g, 4.0mmol) is dissolved in n,N-Dimethylformamide (10mL), is cooled to 0 DEG C,
Sodium hydride (0.176g, 4.4mmol) is added to stir 1 hour.By 2- (trimethylsilyl) ethoxymethyl chlorine (0.8g,
It 4.8mmol) is added drop-wise in reaction solution, is stirred to react at room temperature 4 hours.Ammonium chloride solution (25mL) is added into reaction solution,
It is extracted with methyl tertiary butyl ether(MTBE) (40mL × 3).Merge organic phase, successively uses water (30mL × 2), saturated common salt aqueous solution (30mL
× 1) it washs.Anhydrous magnesium sulfate dries, filters, and filtrate decompression is concentrated, and obtains light yellow liquid 7a (1.6g).
MS m/z(ESI):380.0[M+1]。
Step 2: 5- tert-butyl 3- methyl 2- ((2- (trimethyl silicon substrate) ethyoxyl) methyl) -3b, 4,6a, 7- tetrahydro -
2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -3,5 (6H)-dicarboxylic acid esters (7b)
5-tert-butyl 3-methyl 2-((2-(trimethylsilyl)ethoxy)methyl)-3b,4,6a,7-
tetrahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazole-3,5(6H)-
dicarboxylate
At room temperature, light yellow liquid 7a (1.14g, 3.0mmol) is dissolved in tetrahydrofuran (8mL).- 70 DEG C are cooled to,
It is added dropwise n-butyllithium solution (1.8mL, 4.5mmol, 2.5mol/L), is reacted 0.5 hour in -70 DEG C.At -70 DEG C or less by chloromethane
Sour methyl esters (0.37g, 3.9mmol) is added drop-wise in reaction solution, is kept for -70 DEG C react 4 hours.- 70 DEG C or less addition ammonium chlorides are molten
Liquid (10mL).It is extracted with methyl tertiary butyl ether(MTBE) (25mL × 2), merges organic phase, washed with saturated common salt aqueous solution (20mL × 1)
It washs, anhydrous magnesium sulfate dries, filters, and filtrate decompression is concentrated.Residue uses column chromatography purifying (ethyl acetate/petroleum ether
(v/v)=20:1~5:1), obtain light yellow liquid 7b (0.52g, yield 30.6%).
MS m/z(ESI):338.1[M+1]。
Step 3: methyl 3b, 4,5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -3
Formic acid esters benzene sulfonate (7c)
methyl 3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]
pyrazole-3-carbo-xylate benzenesulfonate
At room temperature, 7b (0.52g, 1.19mmol) is dissolved in anhydrous methanol (10mL), addition benzene sulfonic acid (0.33g,
1.79mmol), heating reflux reaction 16 hours.Reaction solution is concentrated under reduced pressure, light yellow solid 7c (1.22g, yield are obtained
100%).
MS m/z(ESI):208.0[M+1]。
Step 4: methyl 5- ((3R, 5S, 6R) -5- ((tertbutyloxycarbonyl) amino) -6- (2,5- difluorophenyl) tetrahydro -
2H- pyrans -3- base) -3b, 4,5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -3- formic acid
Ester (7d)
methyl 5-((3R,5S,6R)-5-((tert-butoxycarbonyl)amino)-6-(2,5-
difluorophenyl)tetrahydro-2H-pyran-3-yl)-3b,4,5,6,6a,7-hexahydro-2H-pyrrolo
[3',4':3,4]cyclopenta[1,2-c]pyrazole-3-car boxylate
At room temperature, 7c (0.44g, 1.19mmol) is dissolved in n,N-dimethylacetamide (5mL), intermediate 1 is added
(0.37g, 1.13mmol) is stirred at room temperature 1 hour.Three (acetoxyl group) sodium borohydrides (0.31g, 1.47mmol) are added to
In reaction solution, it is stirred to react at room temperature 16 hours.Reaction solution is cooled to 0 DEG C, sequentially adds water (30mL) and ammonium hydroxide (5mL),
White solid is precipitated.Reaction solution is filtered, filter cake is successively washed with water (10mL × 2) and petroleum ether (15mL × 2).It drains, filters
Cake is dissolved with methylene chloride (50mL), and anhydrous magnesium sulfate dries, filters, filtrate decompression is concentrated.Residue silica gel column chromatography
(methylene chloride/methanol (v/v)=100:1~80:1) is isolated and purified, light yellow solid 7d (0.28g, yield 47%) is obtained.
Step 5: methyl 5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -
3b, 4,5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazoles -3- formic acid esters (compound 7)
methyl 5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-
pyran-3-yl)-3b,4,5,6,6a,7-hexahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]
pyrazole-3-carboxylate
At room temperature, 7d (0.08g, 0.154mmol) is dissolved in methylene chloride (2mL), is cooled to 0 DEG C, trifluoro second is added
Sour (2mL), 0 DEG C is reacted 2 hours.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution is added dropwise and adjusts reaction solution pH to 8, uses dichloro
Methane (25mL × 2) extraction.Merge organic phase, is washed with saturated common salt aqueous solution (20mL × 1).Anhydrous magnesium sulfate is dry, mistake
Filter, filtrate decompression is concentrated.Residue prepares plate with thin layer and isolates and purifies (methylene chloride/methanol (v/v)=10:1), and it is white to obtain class
Color solid chemical compound 7 (0.02g, yield 34%).
1H NMR(400MHz,CD3OD):δ7.21-7.09(m,3H),4.28-4.21(d,1H),4.21-4.18(d,1H),
3.89(s,1H),3.71(m,1H),3.55(m,1H),3.04-2.98(m,4H),2.56-2.41(m,6H),1.37(q,1H);
MS m/z(ESI):418.9[M+1]。
Embodiment 8
5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -3b, 4,5,6,6a,
7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazole-3-formamide (compound 8)
5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-
yl)-3b,4,5,6,6a,7-he xahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazole-
3-carboxamide
Step 1: tert-butyl ((2R, 3S, 5R) -5- (3- carbamoyl -3b, 4,6a, 7- tetrahydro -2H- pyrrolo- [3',
4':3,4] cyclopentano [1,2-c] pyrazoles -5 (6H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) carbamic acid
Ester (8a)
tert-butyl((2R,3S,5R)-5-(3-carbamoyl-3b,4,6a,7-tetrahydro-2H-pyrrolo
[3',4':3,4]cyclo-penta[1,2-c]pyrazol-5(6H)-yl)-2-(2,5-difluorophenyl)
tetrahydro-2H-pyran-3-yl)carbamate
At room temperature, 7d (0.1g, 0.19mmol) is dissolved in ammonia/methanol (5mL, 7mol/L), 100 DEG C of sealed cans reactions 16 are small
When.Reaction solution is concentrated, light yellow solid 8a (0.08g, yield 82.3%) is obtained.
MS m/z(ESI):503.9[M+1]。
Step 2: 5- ((3R, 5S, 6R) -5- amino -6- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) -3b, 4,
5,6,6a, 7- hexahydro -2H- pyrrolo- [3', 4':3,4] cyclopentano [1,2-c] pyrazole-3-formamide (compound 8)
5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-
yl)-3b,4,5,6,6a,7-he xahydro-2H-pyrrolo[3',4':3,4]cyclopenta[1,2-c]pyrazole-
3-carboxamide
At room temperature, 8a (0.14g, 0.27mmol) is dissolved in methylene chloride (4mL), is cooled to 0 DEG C, trifluoroacetic acid is added
(4mL) reacts 2 hours in 0 DEG C.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution is added dropwise and adjusts reaction solution pH to 8, uses dichloro
Methane (30mL × 3) extraction.Merge organic phase, is washed with saturated common salt aqueous solution (50mL × 1).Anhydrous magnesium sulfate is dry, mistake
Filter, filtrate decompression is concentrated.Residue prepares plate with thin layer and isolates and purifies (methylene chloride/methanol (v/v)=10:1), and it is white to obtain class
Color solid chemical compound 8 (0.01g, yield 11%).
1H NMR(400MHz,CD3OD):δ7.63(s,1H),7.407-7.404(d,2H),7.002-6.915(m,3H),
5.022-4.796(m,1H),4.22-4.208(d,1H),4.104-4.052(m,4H),3.946-3.925(d,1H),3.685-
3.645(m,1H),3.580-3.541(t,2H),1.417-1.382(m,3H),1.352-1.308(m,3H)。
Embodiment 9
(2- methyl -4b, 5,7a, 8- nafoxidine are simultaneously [3', 4':3,4] by (2R, 3S, 5R) -2- (2,5- difluorophenyl) -5-
Cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) tetrahydro -2H- pyrans -3- amino (compound 9)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methyl-4b,5,7a,8-
tetrahydropyrrolo[3',4':3,4]cycl openta[1,2-d]pyrimidin-6(7H)-yl)tetrahydro-
2H-pyran-3-amine
Step 1: tert-butyl 2- methyl -4b, 5,7a, 8- nafoxidine simultaneously [3', 4':3,4] cyclopentano [1,2-d] pyrimidine -
6 (7H)-formic acid esters (9a)
tert-butyl 2-methyl-4b,5,7a,8-tetrahydropyrrolo[3',4':3,4]cyclopenta
[1,2-d]pyrimidine-6(7H)-carboxylate
At room temperature, methylrnethwirnidamide hydrochloride (0.298g, 3.00mmol) and sodium ethoxide (0.450g, 5.00mmol) are dissolved in
In ethyl alcohol (10mL), stir 15 minutes.The 2D (0.28g, 1.00mmol) being dissolved in ethyl alcohol is added dropwise in reaction solution, 85 DEG C anti-
It answers 12 hours.Reaction solution is concentrated, is extracted with ethyl acetate (30mL × 3), organic phase, saturated common salt aqueous solution (50mL are merged
× 1) it washs, anhydrous magnesium sulfate dries, filters, and is concentrated, obtains brown oil liquid 9a (0.280g, yield 100%).
MS m/z(ESI):276.0[M+1]。
Step 2: 2- methyl -4b, 5,6,7,7a, 8- hexahydropyrrolo simultaneously [3', 4':3,4] cyclopentano [1,2-d] pyrimidine benzene
Sulfonate (9b)
2-methyl-4b,5,6,7,7a,8-hexahydropyrrolo[3',4':3,4]cyclopenta[1,2-d]
pyrimidine benzenesulfonate
At room temperature, 9a (0.26g, 0.95mmol) and benzene sulfonic acid (0.262g, 1.40mmol) are dissolved in methanol (8mL),
68 DEG C are reacted 12 hours.Reaction solution is concentrated under reduced pressure to give brown solid 9b (0.386g, yield 100%).
MS m/z(ESI):176.1[M+1]。
Step 3: tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- methyl -4b, 5,7a, 8- tetrahydro pyrrole
Cough up simultaneously [3', 4':3,4] cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) tetrahydro -2H- pyrans -3- base) carbamate (9c)
tert-butyl
((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methyl-4b,5,7a,8-
tetrahydropyrrolo[3',4':3,4]cyclope nta[1,2-d]pyrimidin-6(7H)-yl)tetrahydro-
2H-pyran-3-yl)carbamate
At room temperature, 9b (0.30g, 0.90mmol) is dissolved in n,N-dimethylacetamide (4mL), intermediate 1 is added
(0.294g, 0.900mmol) is stirred 1 hour at room temperature.Three (acetoxyl group) sodium borohydrides (0.248g, 1.20mmol) are added
Enter into reaction solution, in room temperature reaction 16 hours.Reaction solution is cooled to 0 DEG C, water is sequentially added and ammonium hydroxide adjusts pH to 8, use
Methylene chloride (30mL × 3) extraction.Merge organic phase, washed with saturated common salt aqueous solution (50mL × 1), anhydrous magnesium sulfate is dry
Dry, filtrate is concentrated for filtering, and residue is obtained white with silica gel column chromatography separating purification (methylene chloride/methanol (v/v)=40:1)
Color solid 9c (0.203g, yield 49.0%).
MS m/z(ESI):486.9[M+1]。
Step 4: (2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- methyl -4b, 5,7a, 8- nafoxidine simultaneously [3',
4':3,4] cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) tetrahydro -2H- pyrans -3- amino (compound 9)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methyl-4b,5,7a,8-
tetrahydropyrrolo[3',4':3,4]cycl openta[1,2-d]pyrimidin-6(7H)-yl)tetrahydro-
2H-pyran-3-amine
At room temperature, 9c (0.140g, 0.280mmol) is dissolved in methylene chloride (3mL), is cooled to 0 DEG C, trifluoro second is added
Sour (1.5mL) reacts 2 hours in 0 DEG C.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution is added dropwise and adjusts reaction solution pH to 8, uses
Methylene chloride (30mL × 3) extraction.Merge organic phase, is washed with saturated common salt aqueous solution (50mL × 1).Anhydrous magnesium sulfate is dry
Dry, filtrate decompression is concentrated for filtering, and residue prepares plate with thin layer and isolates and purifies (methylene chloride/methanol (v/v)=10:1),
It obtains compound as white solid 9 (0.030g, yield 28.8%).
MS m/z(ESI):386.9[M+1];
1H NMR(400MHz,CDCl3):δ8.48-8.48(dd,1H),7.18-7.03(m,3H),4.19-4.17(d,
1H),4.15-4.11(m,1H),3.88-3.83(m,1H),3.36-3.32(m,1H),3.28-3.21(m,1H),3.14-3.12
(m,1H),2.98-2.13(m,6H),2.68-2.64(m,3H),2.51-2.44(m,1H),2.38-2.33(m,1H),1.43-
1.33(m,1H)。
Embodiment 10
(simultaneously [3', 4':3,4] cyclopentano [1,2-d] is phonetic for 2- cyclopropyl -4b, 5,7a, 8- nafoxidine by (2R, 3S, 5R) -5-
Pyridine -6 (7H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- amino (compound 10)
(2R,3S,5R)-5-(2-cyclopropyl-4b,5,7a,8-tetrahydropyrrolo[3',4':3,4]
cyclopenta[1,2-d]pyri midin-6(7H)-yl)-2-(2,5-difluorophenyl)tetrahydro-2H-
pyran-3-amine
Step 1: simultaneously [3', 4':3,4] cyclopentano [1,2-d] is phonetic for tert-butyl 2- cyclopropyl -4b, 5,7a, 8- nafoxidine
Pyridine -6 (7H)-formic acid esters (10a)
tert-butyl
2-cyclopropyl-4b,5,7a,8-tetrahydropyrrolo[3',4':3,4]cyclopenta[1,2-d]
pyrimidine-6(7H)-carbox ylate
At room temperature, cyclopropyl amitraz hydrochloride (0.480g, 3.00mmol) and sodium ethoxide (0.45g, 5.00mmol) is molten
In ethyl alcohol (10mL), stirs 15 minutes, the 2D (0.280g, 1.00mmol) being dissolved in ethyl alcohol is added dropwise to reaction solution, in 85
DEG C reaction 12 hours.Reaction solution is concentrated, is added water (30mL), is extracted with ethyl acetate (30mL × 3), organic phase is merged, is used
Saturated common salt aqueous solution (50mL × 1) washing, anhydrous magnesium sulfate dry, filter, filtrate are concentrated, and obtain brown oil liquid
10a (0.308g, yield 100%).
MS m/z(ESI):302.1[M+1]。
Step 2: 2- cyclopropyl -4b, 5,6,7,7a, 8- hexahydropyrrolo simultaneously [3', 4':3,4] cyclopentano [1,2-d] pyrimidine
Benzene sulfonate (10b)
2-cyclopropyl-4b,5,6,7,7a,8-hexahydropyrrolo[3',4':3,4]cyclopenta[1,
2-d]pyrimidine benzenesulfonate
At room temperature, 10a (0.29g, 0.96mmol) and benzene sulfonic acid (0.268g, 1.40mmol) are dissolved in methanol (8mL),
68 DEG C are reacted 12 hours.Reaction solution is concentrated under reduced pressure, brown solid 10b (0.440g, yield 100%) is obtained.
MS m/z(ESI):202.1[M+1]。
Step 3: ((2- cyclopropyl -4b, 5,7a, 8- nafoxidine are simultaneously [3', 4':3,4] by (2R, 3S, 5R) -5- for tert-butyl
Cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- base) carbamate (10c)
tert-butyl
((2R,3S,5R)-5-(2-cyclopropyl-4b,5,7a,8-tetrahydropyrrolo[3',4':3,4]
cyclopenta[1,2-d]pyrimidi n-6(7H)-yl)-2-(2,5-difluorophenyl)tetrahydro-2H-
pyran-3-yl)carbamate
At room temperature, 10b (0.33g, 0.92mmol) is dissolved in n,N-dimethylacetamide (4mL), intermediate 1 is added
(0.301g, 0.92mmol) is stirred at room temperature 1 hour.Three (acetoxyl group) sodium borohydrides (0.253g, 1.21mmol) are added
Into reaction solution, in room temperature reaction 16 hours.It is cooled to 0 DEG C, water (20mL) is sequentially added and ammonium hydroxide adjusts pH to 8, use dichloro
Methane (30mL × 3) extraction.Merge organic phase, washed with saturated common salt aqueous solution (50mL × 1), anhydrous magnesium sulfate is dry, mistake
Filter, filtrate is concentrated, and residue obtains white solid 10c with silica gel column chromatography (methylene chloride/methanol (v/v)=30:1)
(0.114g, yield 24.2%).
MS m/z(ESI):512.9[M+1]。
(2- cyclopropyl -4b, 5,7a, 8- nafoxidine simultaneously [3', the 4':3,4] cyclopentano step 4: (2R, 3S, 5R) -5-
[1,2-d] pyrimidine -6 (7H)-yl) -2- (2,5- difluorophenyl) tetrahydro -2H- pyrans -3- amino (compound 10)
(2R,3S,5R)-5-(2-cyclopropyl-4b,5,7a,8-tetrahydropyrrolo[3',4':3,4]
cyclopenta[1,2-d]pyri midin-6(7H)-yl)-2-(2,5-difluorophenyl)tetrahydro-2H-
pyran-3-amine
At room temperature, 10c (0.10g, 0.20mmol) is dissolved in methylene chloride (3mL), is cooled to 0 DEG C, trifluoro second is added
Sour (1.5mL) reacts 2 hours in 0 DEG C.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution is added dropwise to reaction solution pH to 8, with two
Chloromethanes (30mL × 3) extraction.Merge organic phase, is washed with saturated common salt aqueous solution (50mL × 1).Anhydrous magnesium sulfate is dry,
Filtering, filtrate decompression is concentrated, plate is prepared with thin layer and isolates and purifies (methylene chloride/methanol (v/v)=10:1), obtain white solid
Compound 10 (0.060g, yield 74%).
MS m/z(ESI):412.9[M+1];
1H NMR(400MHz,CDCl3):δ8.39-8.38(dd,1H),7.18-7.03(m,3H),4.22-4.19(d,
1H),4.17-4.10(m,1H),3.85-3.79(m,1H),3.28-3.22(m,1H),3.15-3.07(m,1H),2.97-2.63
(m,6H),2.50-2.44(m,1H),2.38-2.34(m,1H),2.22-2.14(m,1H),1.45-1.31(m,2H),1.09-
1.01(m,4H)。
Embodiment 11
(2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (trifluoromethyl) -4b, 5,7a, 8- nafoxidine simultaneously [3',
4':3,4] cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) tetrahydro -2H- pyrans -3- amino trifluoroacetate (compound 11)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(trifluoromethyl)-4b,5,7a,8-
tetrahydropyrrolo[3',4':3,4]cyclopenta[1,2-d]pyrimidin-6(7H)-yl)tetrahydro-
2H-pyran-3-amine 2,2,2-trifluoroacetate
Step 1: tert-butyl 2- (trifluoromethyl) -4b, 5,7a, 8- nafoxidine simultaneously [3', 4':3,4] cyclopentano [1,2-
D] pyrimidine -6 (7H)-formic acid esters (11a)
tert-butyl
2-(trifluoromethyl)-4b,5,7a,8-tetrahydropyrrolo[3',4':3,4]cyclopenta
[1,2-d]pyrimidine-6(7H)-c arboxylate
At room temperature, by trifluoromethyl amitraz hydrochloride (0.654g, 5.80mmol) and sodium ethoxide (0.646g, 9.50mmol)
It is dissolved in ethyl alcohol (36mL), stirs minute, the 2D (0.54g, 1.90mmol) for being dissolved in ethyl alcohol is added dropwise to reaction solution, 85 DEG C of reactions
12 hours.Reaction solution is concentrated, is extracted with ethyl acetate (30mL × 3), merges organic phase, with saturated common salt aqueous solution (50mL
× 1) it washs, anhydrous magnesium sulfate dries, filters, filtrate is concentrated, and obtains brown oil liquid 11a (0.398g, yield 63%).
MS m/z(ESI):330.1[M+1]。
Step 2: 2- (trifluoromethyl) -4b, 5,6,7,7a, 8- hexahydropyrrolo simultaneously [3', 4':3,4] cyclopentano [1,2-d]
Pyrimidine benzene sulfonate (11b)
2-(trifluoromethyl)-4b,5,6,7,7a,8-hexahydropyrrolo[3',4':3,4]
cyclopenta[1,2-d]pyrimidine benzenesulfonate
At room temperature, 11a (0.39g, 1.2mmol) and benzene sulfonic acid (0.333g, 1.80mmol) are dissolved in methanol (16mL),
68 DEG C are reacted 12 hours.Reaction solution is concentrated under reduced pressure, brown solid 11b (0.440g, yield 100%) is obtained.
MS m/z(ESI):202.1[M+1]。
Step 3: tert-butyl ((2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (trifluoromethyl) -4b, 5,7a, 8-
Nafoxidine simultaneously [3', 4':3,4] cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) tetrahydro -2H- pyrans -3- base) carbamate
(11c)
tert-butyl
((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(trifluoromethyl)-4b,5,7a,8-
tetrahydropyrrolo[3',4':3,4]cyclopenta[1,2-d]pyrimidin-6(7H)-yl)tetrahydro-
2H-pyran-3-yl)carbamate
At room temperature, 11b (0.637g, 0.90mmol) is dissolved in n,N-dimethylacetamide (5mL), intermediate 1 is added
(0.295g, 0.90mmol) is stirred at room temperature 1 hour.Three (acetoxyl group) sodium borohydrides (0.318g, 1.20mmol) are added to
In reaction solution, in room temperature reaction 16 hours.Reaction solution is cooled to 0 DEG C, water is sequentially added and ammonium hydroxide adjusts pH to 8, use dichloro
Methane (30mL × 3) extraction.Merge organic phase, washed with saturated common salt aqueous solution (50mL × 1), anhydrous magnesium sulfate is dry, mistake
Filter, filtrate is concentrated, with silica gel column chromatography separating purification (methylene chloride/methanol (v/v)=30:1), obtains light yellow solid 11c
(0.130g, yield 26%).
MS m/z(ESI):541.2[M+1]。
Step 4: (2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (trifluoromethyl) -4b, 5,7a, 8- nafoxidine
And [3', 4':3,4] cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) tetrahydro -2H- pyrans -3- amino (11d)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(trifluoromethyl)-4b,5,7a,8-
tetrahydropyrrolo[3',4':3,4]cyclopenta[1,2-d]pyrimidin-6(7H)-yl)tetrahydro-
2H-pyran-3-amine
At room temperature, 11c (0.13g, 0.24mmol) is dissolved in methylene chloride (3mL), is cooled to 0 DEG C, trifluoro second is added
Sour (1.5mL), 0 DEG C is reacted 2 hours.Reaction solution is concentrated under reduced pressure, sodium bicarbonate solution is added dropwise and adjusts reaction solution pH to 8, with two
Chloromethanes (30mL × 3) extraction.Merge organic phase, is washed with saturated common salt aqueous solution (50mL × 1).Anhydrous magnesium sulfate is dry,
Filtering, filtrate decompression is concentrated, thin layer prepares plate and isolates and purifies (methylene chloride/methanol (v/v)=10:1), obtains white solid
11d (0.070g, yield 69.8%).
MS m/z(ESI):441.2[M+1]。
Step 5: (2R, 3S, 5R) -2- (2,5- difluorophenyl) -5- (2- (trifluoromethyl) -4b, 5,7a, 8- nafoxidine
And [3', 4':3,4] cyclopentano [1,2-d] pyrimidine -6 (7H)-yl) tetrahydro -2H- pyrans -3- amino 2,2,2- trifluoroacetate
(compound 11)
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(trifluoromethyl)-4b,5,7a,8-
tetrahydropyrrolo[3',4':3,4]cyclopenta[1,2-d]pyrimidin-6(7H)-yl)tetrahydro-
2H-pyran-3-amine 2,2,2-trifluoroacetate
At room temperature, 11d (0.07g, 0.16mmol) is dissolved in methylene chloride (10mL), trifluoroacetic acid (1mL) is added dropwise and stirs
It mixes 10 minutes.Reaction solution is concentrated, compound as white solid 11 (88mg) is obtained.
MS m/z(ESI):441.2[M+1];
1H NMR(400MHz,CDCl3):δ8.74-8.73(dd,1H),7.18-7.04(m,3H),4.22-4.13(d,
1H),4.16-4.13(m,1H),3.95(m,1H),3.48-3.41(m,1H),3.31-3.23(m,2H),3.01-2.92(m,
3H),2.84-2.75(m,3H),2.55-2.49(m,1H),2.36-2.34(m,1H),1.44-1.28(m,1H)。
Biological test
1, the external enzyme activity determination of DPP-IV
DPP-IV using the zymetology reaction assay the compounds of this invention of recombined human DPP-IV and H-Ala-Pro-AFC is external
Enzyme activity.Buffer, to be measured is prepared according to DPP-IV Fluorescent ActivityAssay Kit (BPS Bioscience)
Sample working solution, DPP-IV enzyme dilution and AFC substrate dilution.
Prepare 96 orifice plates, 80 μ L buffers are first added in every hole, and 5 μ L DPP-AFC- substrates are added later.It adds different dense
5 μ L buffers are added to test sample working solution, every 5 μ L of hole, blank group in degree.10 μ L DPP-IV finally are added in test group control
10 μ L buffers are added in blank control group in enzyme.Statistical analysis is carried out to data with 7.5 software of Origin, obtains each test
The IC of compound50Value, the results are shown in Table 1.
The external enzyme activity measurement result of table 1DPP-IV
Serial number | Compound number | IC50(μM) |
1 | Compound 1-1 | 0.0595 |
2 | Compound 1-2 | 0.103 |
3 | Compound 3-1 | 0.0332 |
4 | Compound 3-2 | 0.0188 |
5 | Compound 4-1a and compound 4-2a mixture | 0.0040 |
6 | Compound 5-1a and compound 5-2a mixture | 0.0127 |
7 | Compound 6 | 0.0452 |
8 | Compound 7 | 0.0447 |
9 | Compound 9 | 0.0114 |
10 | Compound 10 | 0.0210 |
Conclusion: the compounds of this invention has the inhibitory activity of apparent DPP-IV enzyme.
2, oral glucose tolerance test
Utilize hypoglycemic effect of oral glucose tolerance test (OGTT) evaluation the compounds of this invention in mouse.It uses
Animal is SPF grades of ICR mouse, four week old, half male and half female, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd., animal
Produce quality certification number: SCXK (capital) 2012-001.Then STZ solution is continuously injected intraperitoneally in first feeding high lipid food one week
(50mg/kg) 4 days.It is grouped according to the basal plasma glucose value after fasting, every group 10.Test-compound is with 5%DMSO-5%
Solutol-90% normal saline at 1mg/mL suspension.Gastric infusion, dosage 10mg/kg.Blank control group
Give 5%DMSO-5%solutol-90% physiological saline.10% glucose solution (1g/kg) is given after administration 15min,
And in 0,15,30,45,60,120min, using Johnson & Johnson, surely bold and unconstrained Instrument for Measuring Blood Sugar measures the blood glucose value of each mouse, calculate medicine-when
Area under the curve (AUC) reduces ratio.Experimental result is shown in Table 2.
2 Mouse oral glucose tolerance test evaluation result of table
Serial number | Compound number | AUC reduces ratio (%) |
1 | Compound 9 | 29.01 |
2 | Compound 10 | 26.08 |
Conclusion: the compounds of this invention has preferable hypoglycemic effect, can obviously reduce blood glucose after the administration of mouse single oral.
Claims (9)
1. ternary shown in logical formula (I) condenses cyclosubstituted amino hexatomic ring analog derivative or its pharmaceutically acceptable salt:
Wherein:
X is selected from-O-;
W is selected from
R1And R1cSelected from H, R1aAnd R1dSelected from F, R1bSelected from H;
R2Selected from H, methyl, ethyl, propyl,
R3Selected from H, methyl, ethyl ,-CF3、
R4Selected from methyl ,-CF3Or
2. it is derivative that ternary shown in the logical formula (I) of any one according to claim 1 condenses cyclosubstituted amino hexatomic ring class
Object or its pharmaceutically acceptable salt are selected from:
3. ternary described according to claim 1~any one of 2 condenses cyclosubstituted amino hexatomic ring analog derivative or its medicine
Acceptable salt on, wherein the salt is selected from sodium salt, sylvite, calcium salt, magnesium salts, barium salt, ammonium salt, front three amine salt, triethylamine
Salt, pyridiniujm, picoline salt, 2,6- lutidines salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, cyclohexylamine
Salt, dicyclohexyl ammonium salt, hydrochloride, hydrobromate, sulfate, nitrate, phosphate, formates, trifluoroacetate, acetic acid
Salt, maleate, tartrate, citrate, succinate, mandelate, fumarate, malonate, malate, 2-
Hydracrylate, oxalates, oxyacetate, salicylate, glucuronate salt, galacturonic hydrochlorate, citrate, door winter ammonia
Hydrochlorate, glutamate, benzoate, cinnamate, tosilate, benzene sulfonate, mesylate, esilate, trifluoro
Mesylate or their combination.
4. a kind of pharmaceutical composition, the composition include: effective dose according to claim 1~any one of 2 described in
Ternary shown in logical formula (I) condenses cyclosubstituted amino hexatomic ring analog derivative or its pharmaceutically acceptable salt, or further
Including one or more other therapeutic agents and pharmaceutically acceptable carrier or excipient.
5. pharmaceutical composition according to claim 4, wherein the other therapeutic agents include:
(a) DPP-IV inhibitor or pharmaceutically acceptable salt, and/or
(b) SGLT-2 inhibitor or pharmaceutically acceptable salt, and/or
(c) biguanides, thiazolidinediones, sulfonylurea, column how class, alpha-glucosidase restrainer or glucagon
- 1 analog of peptide or its pharmaceutically acceptable salt or prodrug.
6. pharmaceutical composition according to claim 5, wherein the SGLT-2 inhibitor is selected from Dapagliflozin, Kan Gelie
Only, A Gelie is net, En Palie is net, Yi Palie is net, Tuo Fulie is net, Lu Silie is net, Rui Gelie is net, Sergliflozin or support column are net;
DPP-IV inhibitor be selected from BI 1356, sitagliptin, vildagliptin, Egelieting, saxagliptin, Na Lieting, Ka Gelie
Ge Lieting, gigue column spit of fland or song Ge Lieting, dutogliptin, are replaced at melogliptin in spit of fland;Biguanides therapeutic agent is selected from melbine or benzene
Second biguanides;Thiazolidinediones therapeutic agent is selected from Ciglitazone, pioglitazone, Rosiglitazone, troglitazone, Fa Gelie ketone or reaches
Lattice column ketone, sulfonylurea treatment agent are selected from Glimepiride, orinase, Glibornuride, glibenclamide, gliquidone, lattice column
Pyrazine or gliclazide, how class therapeutic agent is selected from Nateglinide, Repaglinide or Mitiglinide, alpha-glucosidase restrainer to column
Selected from acarbose, voglibose or Miglitol, glucagon-like peptide-1 analogs are selected from Exenatide or Li Lalu
Peptide.
7. leading to ternary shown in formula (I) described in any one of claim 1~2 condenses cyclosubstituted amino hexatomic ring analog derivative
Or composition described in any one of its pharmaceutically acceptable salt or claim 4~6 is preparing dipeptidyl peptidase-IV suppression
Application in preparation.
8. application according to claim 7, wherein the dipeptidyl peptidase-iv inhibitor is used to prepare treatment metabolism
Property disease drug, wherein the metabolic disease be selected from diabetes, diabetic retinopathy, diabetic neuropathy,
Nephrosis, insulin resistance, hyperglycemia, hyperinsulinemia, fatty acid or the raised level of glycerol, hyperlipemia
Disease, obesity, Hypertriglyceridemia, X syndrome, diabetic complication, atherosclerosis or hypertension.
9. application according to claim 8, wherein the diabetes are type-2 diabetes mellitus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510267948.8A CN105085530B (en) | 2014-05-23 | 2015-05-22 | Ternary condenses cyclosubstituted amino hexatomic ring analog derivative and its application in medicine |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410223216 | 2014-05-23 | ||
CN2014102232164 | 2014-05-23 | ||
CN201510267948.8A CN105085530B (en) | 2014-05-23 | 2015-05-22 | Ternary condenses cyclosubstituted amino hexatomic ring analog derivative and its application in medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105085530A CN105085530A (en) | 2015-11-25 |
CN105085530B true CN105085530B (en) | 2019-01-04 |
Family
ID=54566945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510267948.8A Expired - Fee Related CN105085530B (en) | 2014-05-23 | 2015-05-22 | Ternary condenses cyclosubstituted amino hexatomic ring analog derivative and its application in medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105085530B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111269218A (en) * | 2018-12-04 | 2020-06-12 | 四川海思科制药有限公司 | Trifluoromethyl substituted aminopyrane ring derivatives, and compositions and uses thereof |
CN111057059B (en) * | 2019-11-25 | 2022-04-26 | 广东省测试分析研究所(中国广州分析测试中心) | Benzodithiepyrrole compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007097931A2 (en) * | 2006-02-15 | 2007-08-30 | Merck & Co., Inc. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
CN101410400A (en) * | 2006-03-28 | 2009-04-15 | 默克公司 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
WO2011103256A1 (en) * | 2010-02-22 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
CN102272136A (en) * | 2008-11-13 | 2011-12-07 | 默沙东公司 | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
-
2015
- 2015-05-22 CN CN201510267948.8A patent/CN105085530B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007097931A2 (en) * | 2006-02-15 | 2007-08-30 | Merck & Co., Inc. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
CN101410400A (en) * | 2006-03-28 | 2009-04-15 | 默克公司 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
CN102272136A (en) * | 2008-11-13 | 2011-12-07 | 默沙东公司 | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2011103256A1 (en) * | 2010-02-22 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
Also Published As
Publication number | Publication date |
---|---|
CN105085530A (en) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105294694B (en) | Amino hexatomic ring analog derivative and its application in medicine | |
CN112566637B (en) | GLP-1 receptor agonists and uses thereof | |
CN105518008B (en) | Amino pyrans ring derivatives and combinations thereof and application | |
CA2947338C (en) | Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor | |
US8394952B2 (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
KR20210019529A (en) | GLP-1 receptor agonists and uses thereof | |
TW201843149A (en) | Farnesoid x receptor agonists and uses thereof | |
US20120238549A1 (en) | Nuclear Hormone Receptor Modulators | |
CN105037367A (en) | Amino six-membered ring derivative and application thereof in medicines | |
JP2021526123A (en) | Autotaxin inhibitors and their use | |
US11753416B2 (en) | Compounds and compositions for inducing chondrogenesis | |
CN105085530B (en) | Ternary condenses cyclosubstituted amino hexatomic ring analog derivative and its application in medicine | |
KR20220002903A (en) | Heteroaryl (heterocyclyl) methanol compounds useful for the treatment of hyperglycemia | |
CN106458987B (en) | For treating the pyrrolidines GPR40 regulator of disease such as diabetes | |
CN102372701A (en) | Azabicyclo hexane derivative, preparation method, and application of azabicyclo hexane derivative in medicine | |
TWI682933B (en) | Amino six-membered ring derivatives substituted with three-membered fused rings and their application in medicine | |
TWI681962B (en) | Amine six-membered ring derivatives and their application in medicine | |
CN109721555B (en) | Acylated piperazine compound and application thereof | |
TW202024052A (en) | Farnesoid x receptor agonists and uses thereof | |
CN113015736A (en) | 6-hydroxy-8-oxatricyclo [3.2.1.02,4] octane-2-carboxamide derivatives for inducing chondrogenesis to treat joint damage | |
TW201708223A (en) | Amino six-membered cyclic derivative and its application in medicine being an inhibitor for curing diabetes and reducing the side effects | |
DE102004025552A1 (en) | New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis | |
DE102004017739A1 (en) | New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190104 |